original_sentence	e1	e2	relation_type	metadata	preprocessed_sentence
Tamoxifen, an estrogen antagonist, is the standard hormone treatment for breast cancer. 	Tamoxifen	estrogen antagonist	none	{'e1': {'word': 'Tamoxifen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s1.e0'}, 'e2': {'word': 'estrogen antagonist', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d209.s1.e1'}, 'sentence_id': 'DDI-MedLine.d209.s1'}	Tamoxifen estrogen antagonist standard hormone treatment breast cancer
Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. 	Paroxetine	fluoxetine	none	{'e1': {'word': 'Paroxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s5.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d209.s5.e1'}, 'sentence_id': 'DDI-MedLine.d209.s5'}	Paroxetine fluoxetine reduce plasma concentration endoxifen NUMBER %
Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. 	Paroxetine	endoxifen	mechanism	{'e1': {'word': 'Paroxetine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d209.s5.e0'}, 'e2': {'word': 'endoxifen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d209.s5.e2'}, 'sentence_id': 'DDI-MedLine.d209.s5'}	Paroxetine fluoxetine reduce plasma concentration endoxifen NUMBER %
Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. 	fluoxetine	endoxifen	mechanism	{'e1': {'word': 'fluoxetine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d209.s5.e1'}, 'e2': {'word': 'endoxifen', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d209.s5.e2'}, 'sentence_id': 'DDI-MedLine.d209.s5'}	Paroxetine fluoxetine reduce plasma concentration endoxifen NUMBER %
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	tamoxifen	SSRI antidepressants	advise	{'e1': {'word': 'tamoxifen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d209.s9.e0'}, 'e2': {'word': 'SSRI antidepressants', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d209.s9.e1'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated tamoxifen breast cancer especially SSRI antidepressants paroxetine fluoxetine
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	tamoxifen	paroxetine	advise	{'e1': {'word': 'tamoxifen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d209.s9.e0'}, 'e2': {'word': 'paroxetine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d209.s9.e2'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated tamoxifen breast cancer especially SSRI antidepressants paroxetine fluoxetine
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	tamoxifen	fluoxetine	advise	{'e1': {'word': 'tamoxifen', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d209.s9.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d209.s9.e3'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated tamoxifen breast cancer especially SSRI antidepressants paroxetine fluoxetine
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	SSRI antidepressants	paroxetine	none	{'e1': {'word': 'SSRI antidepressants', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d209.s9.e1'}, 'e2': {'word': 'paroxetine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d209.s9.e2'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated tamoxifen breast cancer especially SSRI antidepressants paroxetine fluoxetine
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	SSRI antidepressants	fluoxetine	none	{'e1': {'word': 'SSRI antidepressants', 'word_index': [(13, 14)], 'id': 'DDI-MedLine.d209.s9.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d209.s9.e3'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated tamoxifen breast cancer especially SSRI antidepressants paroxetine fluoxetine
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. 	paroxetine	fluoxetine	none	{'e1': {'word': 'paroxetine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d209.s9.e2'}, 'e2': {'word': 'fluoxetine', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d209.s9.e3'}, 'sentence_id': 'DDI-MedLine.d209.s9'}	better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated tamoxifen breast cancer especially SSRI antidepressants paroxetine fluoxetine
Depression does not always require antidepressant drug therapy, and antidepressants have no proven preventive impact on hot flushes linked to the menopause. 	antidepressant drug	antidepressants	none	{'e1': {'word': 'antidepressant drug', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d209.s10.e0'}, 'e2': {'word': 'antidepressants', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d209.s10.e1'}, 'sentence_id': 'DDI-MedLine.d209.s10'}	Depression always require antidepressant drug therapy antidepressants proven preventive impact hot flushes linked menopause
If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.	antidepressant	tamoxifen	advise	{'e1': {'word': 'antidepressant', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d209.s11.e0'}, 'e2': {'word': 'tamoxifen', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d209.s11.e1'}, 'sentence_id': 'DDI-MedLine.d209.s11'}	certain cases antidepressant considered necessary may advisable replace tamoxifen anastrozole
If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.	antidepressant	anastrozole	none	{'e1': {'word': 'antidepressant', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d209.s11.e0'}, 'e2': {'word': 'anastrozole', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d209.s11.e2'}, 'sentence_id': 'DDI-MedLine.d209.s11'}	certain cases antidepressant considered necessary may advisable replace tamoxifen anastrozole
If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.	tamoxifen	anastrozole	none	{'e1': {'word': 'tamoxifen', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d209.s11.e1'}, 'e2': {'word': 'anastrozole', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d209.s11.e2'}, 'sentence_id': 'DDI-MedLine.d209.s11'}	certain cases antidepressant considered necessary may advisable replace tamoxifen anastrozole
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Ticagrelor	Brilinta	none	{'e1': {'word': 'Ticagrelor', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e0'}, 'e2': {'word': 'Brilinta', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d193.s0.e1'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	Ticagrelor Brilinta better clopidogrel Plavix
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Ticagrelor	clopidogrel	none	{'e1': {'word': 'Ticagrelor', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s0.e2'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	Ticagrelor Brilinta better clopidogrel Plavix
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Ticagrelor	Plavix	none	{'e1': {'word': 'Ticagrelor', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d193.s0.e0'}, 'e2': {'word': 'Plavix', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d193.s0.e3'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	Ticagrelor Brilinta better clopidogrel Plavix
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Brilinta	clopidogrel	none	{'e1': {'word': 'Brilinta', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d193.s0.e1'}, 'e2': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s0.e2'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	Ticagrelor Brilinta better clopidogrel Plavix
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	Brilinta	Plavix	none	{'e1': {'word': 'Brilinta', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d193.s0.e1'}, 'e2': {'word': 'Plavix', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d193.s0.e3'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	Ticagrelor Brilinta than ( Plavix )
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)	clopidogrel	Plavix	none	{'e1': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s0.e2'}, 'e2': {'word': 'Plavix', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d193.s0.e3'}, 'sentence_id': 'DDI-MedLine.d193.s0'}	Ticagrelor Brilinta better clopidogrel Plavix
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	ticagrelor	Brilinta	none	{'e1': {'word': 'ticagrelor', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d193.s1.e0'}, 'e2': {'word': 'Brilinta', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s1.e1'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	FDA approved ticagrelor Brilinta AstraZeneca oral antiplatelet drug use low dose aspirin reduce rate thrombotic cardiovascular events patients acute coronary syndrome ACS
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	ticagrelor	antiplatelet drug	none	{'e1': {'word': 'ticagrelor', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d193.s1.e0'}, 'e2': {'word': 'antiplatelet drug', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d193.s1.e2'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	FDA approved ticagrelor Brilinta AstraZeneca oral antiplatelet drug use low dose aspirin reduce rate thrombotic cardiovascular events patients acute coronary syndrome ACS
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	ticagrelor	aspirin	effect	{'e1': {'word': 'ticagrelor', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d193.s1.e0'}, 'e2': {'word': 'aspirin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d193.s1.e3'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	FDA approved ticagrelor Brilinta AstraZeneca oral antiplatelet drug use low dose aspirin reduce rate thrombotic cardiovascular events patients acute coronary syndrome ACS
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	Brilinta	antiplatelet drug	none	{'e1': {'word': 'Brilinta', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s1.e1'}, 'e2': {'word': 'antiplatelet drug', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d193.s1.e2'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	FDA approved ticagrelor Brilinta AstraZeneca oral antiplatelet drug use low dose aspirin reduce rate thrombotic cardiovascular events patients acute coronary syndrome ACS
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	Brilinta	aspirin	effect	{'e1': {'word': 'Brilinta', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s1.e1'}, 'e2': {'word': 'aspirin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d193.s1.e3'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	FDA approved ticagrelor Brilinta AstraZeneca oral antiplatelet drug use low dose aspirin reduce rate thrombotic cardiovascular events patients acute coronary syndrome ACS
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 	antiplatelet drug	aspirin	none	{'e1': {'word': 'antiplatelet drug', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d193.s1.e2'}, 'e2': {'word': 'aspirin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d193.s1.e3'}, 'sentence_id': 'DDI-MedLine.d193.s1'}	FDA approved ticagrelor Brilinta AstraZeneca oral antiplatelet drug use low dose aspirin reduce rate thrombotic cardiovascular events patients acute coronary syndrome ACS
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	clopidogrel	Plavix	none	{'e1': {'word': 'clopidogrel', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d193.s2.e0'}, 'e2': {'word': 'Plavix', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d193.s2.e1'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	compete clopidogrel Plavix prasugrel Effient use
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	clopidogrel	prasugrel	none	{'e1': {'word': 'clopidogrel', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d193.s2.e0'}, 'e2': {'word': 'prasugrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s2.e2'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	compete clopidogrel Plavix prasugrel Effient use
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	clopidogrel	Effient	none	{'e1': {'word': 'clopidogrel', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d193.s2.e0'}, 'e2': {'word': 'Effient', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d193.s2.e3'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	compete clopidogrel Plavix prasugrel Effient use
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	Plavix	prasugrel	none	{'e1': {'word': 'Plavix', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d193.s2.e1'}, 'e2': {'word': 'prasugrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s2.e2'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	compete clopidogrel Plavix prasugrel Effient use
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	Plavix	Effient	none	{'e1': {'word': 'Plavix', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d193.s2.e1'}, 'e2': {'word': 'Effient', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d193.s2.e3'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	compete clopidogrel Plavix prasugrel Effient use
It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. 	prasugrel	Effient	none	{'e1': {'word': 'prasugrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d193.s2.e2'}, 'e2': {'word': 'Effient', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d193.s2.e3'}, 'sentence_id': 'DDI-MedLine.d193.s2'}	compete clopidogrel Plavix prasugrel Effient use
"Influence of piperine on ibuprofen induced antinociception and its pharmacokinetics.
"	piperine	ibuprofen	none	{'e1': {'word': 'piperine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d195.s0.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d195.s0.e1'}, 'sentence_id': 'DDI-MedLine.d195.s0'}	Influence piperine ibuprofen induced antinociception pharmacokinetics
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	piperine	ibuprofen	effect	{'e1': {'word': 'piperine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d195.s4.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d195.s4.e1'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	present study piperine NUMBER mg / kg significantly increased dose dependent antinociceptive activity ibuprofen evaluated acetic acid writhing formalin test administered ibuprofen
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	piperine	acetic acid	none	{'e1': {'word': 'piperine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d195.s4.e0'}, 'e2': {'word': 'acetic acid', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d195.s4.e2'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	present study piperine NUMBER mg / kg significantly increased dose dependent antinociceptive activity ibuprofen evaluated acetic acid writhing formalin test administered ibuprofen
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	piperine	ibuprofen	none	{'e1': {'word': 'piperine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d195.s4.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d195.s4.e3'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	present study piperine NUMBER mg / kg significantly increased dose dependent antinociceptive activity ibuprofen evaluated acetic acid writhing formalin test administered ibuprofen
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	ibuprofen	acetic acid	none	{'e1': {'word': 'ibuprofen', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d195.s4.e1'}, 'e2': {'word': 'acetic acid', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d195.s4.e2'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	present study piperine NUMBER mg / kg significantly increased dose dependent antinociceptive activity ibuprofen evaluated acetic acid writhing formalin test administered ibuprofen
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	ibuprofen	ibuprofen	none	{'e1': {'word': 'ibuprofen', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d195.s4.e1'}, 'e2': {'word': 'ibuprofen', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d195.s4.e3'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	present study piperine NUMBER mg / kg significantly increased dose dependent antinociceptive activity ibuprofen evaluated acetic acid writhing formalin test administered ibuprofen
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen. 	acetic acid	ibuprofen	none	{'e1': {'word': 'acetic acid', 'word_index': [(15, 16)], 'id': 'DDI-MedLine.d195.s4.e2'}, 'e2': {'word': 'ibuprofen', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d195.s4.e3'}, 'sentence_id': 'DDI-MedLine.d195.s4'}	present study piperine NUMBER mg / kg significantly increased dose dependent antinociceptive activity ibuprofen evaluated acetic acid writhing formalin test administered ibuprofen
Ibuprofen plasma concentration was also increased when it was administered with piperine. 	Ibuprofen	piperine	mechanism	{'e1': {'word': 'Ibuprofen', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d195.s5.e0'}, 'e2': {'word': 'piperine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d195.s5.e1'}, 'sentence_id': 'DDI-MedLine.d195.s5'}	Ibuprofen plasma concentration also increased administered piperine
The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. 	ibuprofen	piperine	mechanism	{'e1': {'word': 'ibuprofen', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d195.s6.e0'}, 'e2': {'word': 'piperine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d195.s6.e1'}, 'sentence_id': 'DDI-MedLine.d195.s6'}	synergistic antinociception activity ibuprofen administered piperine attributed increased plasma concentration ibuprofen
The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. 	ibuprofen	ibuprofen	none	{'e1': {'word': 'ibuprofen', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d195.s6.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d195.s6.e2'}, 'sentence_id': 'DDI-MedLine.d195.s6'}	synergistic antinociception activity ibuprofen administered piperine attributed increased plasma concentration ibuprofen
The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen. 	piperine	ibuprofen	none	{'e1': {'word': 'piperine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d195.s6.e1'}, 'e2': {'word': 'ibuprofen', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d195.s6.e2'}, 'sentence_id': 'DDI-MedLine.d195.s6'}	synergistic antinociception activity ibuprofen administered piperine attributed increased plasma concentration ibuprofen
From this study it can be concluded that piperine can be used as a bioenhancer along with ibuprofen.	piperine	ibuprofen	effect	{'e1': {'word': 'piperine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d195.s7.e0'}, 'e2': {'word': 'ibuprofen', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d195.s7.e1'}, 'sentence_id': 'DDI-MedLine.d195.s7'}	study concluded piperine used bioenhancer along ibuprofen
"Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study.
"	Antidepressant	warfarin	none	{'e1': {'word': 'Antidepressant', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s0.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d218.s0.e1'}, 'sentence_id': 'DDI-MedLine.d218.s0'}	Antidepressant warfarin interaction associated gastrointestinal bleeding risk case control study
We sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.	antidepressant	warfarin	none	{'e1': {'word': 'antidepressant', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s3.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d218.s3.e1'}, 'sentence_id': 'DDI-MedLine.d218.s3'}	sought evaluate whether initiation antidepressant increases risk hospitalization gastrointestinal bleeding warfarin users
In total, 430,455 warfarin users contributed 407,370 person-years of warfarin use. 	warfarin	warfarin	none	{'e1': {'word': 'warfarin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d218.s5.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d218.s5.e1'}, 'sentence_id': 'DDI-MedLine.d218.s5'}	total NUMBER warfarin users contributed NUMBER person years warfarin use
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	Warfarin	citalopram	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s8.e0'}, 'e2': {'word': 'citalopram', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d218.s8.e1'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	Warfarin users increased odds ratio gastrointestinal bleeding upon initiation citalopram = NUMBER NUMBER % CI NUMBER - NUMBER fluoxetine = NUMBER NUMBER % CI NUMBER - NUMBER paroxetine = NUMBER NUMBER % CI NUMBER - NUMBER amitriptyline = NUMBER NUMBER % CI NUMBER - NUMBER
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	Warfarin	fluoxetine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s8.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d218.s8.e2'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	Warfarin users increased odds ratio gastrointestinal bleeding upon initiation citalopram = NUMBER NUMBER % CI NUMBER - NUMBER fluoxetine = NUMBER NUMBER % CI NUMBER - NUMBER paroxetine = NUMBER NUMBER % CI NUMBER - NUMBER amitriptyline = NUMBER NUMBER % CI NUMBER - NUMBER
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	Warfarin	paroxetine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s8.e0'}, 'e2': {'word': 'paroxetine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d218.s8.e3'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	Warfarin users increased odds ratio gastrointestinal bleeding upon initiation citalopram = NUMBER NUMBER % CI NUMBER - NUMBER fluoxetine = NUMBER NUMBER % CI NUMBER - NUMBER paroxetine = NUMBER NUMBER % CI NUMBER - NUMBER amitriptyline = NUMBER NUMBER % CI NUMBER - NUMBER
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	Warfarin	amitriptyline	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s8.e0'}, 'e2': {'word': 'amitriptyline', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d218.s8.e4'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	Warfarin users increased odds ratio gastrointestinal bleeding upon initiation citalopram = NUMBER NUMBER % CI NUMBER - NUMBER fluoxetine = NUMBER NUMBER % CI NUMBER - NUMBER paroxetine = NUMBER NUMBER % CI NUMBER - NUMBER amitriptyline = NUMBER NUMBER % CI NUMBER - NUMBER
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	citalopram	fluoxetine	none	{'e1': {'word': 'citalopram', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d218.s8.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d218.s8.e2'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	Warfarin users increased odds ratio gastrointestinal bleeding upon initiation citalopram = NUMBER NUMBER % CI NUMBER - NUMBER fluoxetine = NUMBER NUMBER % CI NUMBER - NUMBER paroxetine = NUMBER NUMBER % CI NUMBER - NUMBER amitriptyline = NUMBER NUMBER % CI NUMBER - NUMBER
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	citalopram	paroxetine	none	{'e1': {'word': 'citalopram', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d218.s8.e1'}, 'e2': {'word': 'paroxetine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d218.s8.e3'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	Warfarin users increased odds ratio gastrointestinal bleeding upon initiation citalopram = NUMBER NUMBER % CI NUMBER - NUMBER fluoxetine = NUMBER NUMBER % CI NUMBER - NUMBER paroxetine = NUMBER NUMBER % CI NUMBER - NUMBER amitriptyline = NUMBER NUMBER % CI NUMBER - NUMBER
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	citalopram	amitriptyline	none	{'e1': {'word': 'citalopram', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d218.s8.e1'}, 'e2': {'word': 'amitriptyline', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d218.s8.e4'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	Warfarin users increased odds ratio gastrointestinal bleeding upon initiation citalopram = NUMBER NUMBER % CI NUMBER - NUMBER fluoxetine = NUMBER NUMBER % CI NUMBER - NUMBER paroxetine = NUMBER NUMBER % CI NUMBER - NUMBER amitriptyline = NUMBER NUMBER % CI NUMBER - NUMBER
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	fluoxetine	paroxetine	none	{'e1': {'word': 'fluoxetine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d218.s8.e2'}, 'e2': {'word': 'paroxetine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d218.s8.e3'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	Warfarin users increased odds ratio gastrointestinal bleeding upon initiation citalopram = NUMBER NUMBER % CI NUMBER - NUMBER fluoxetine = NUMBER NUMBER % CI NUMBER - NUMBER paroxetine = NUMBER NUMBER % CI NUMBER - NUMBER amitriptyline = NUMBER NUMBER % CI NUMBER - NUMBER
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	fluoxetine	amitriptyline	none	{'e1': {'word': 'fluoxetine', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d218.s8.e2'}, 'e2': {'word': 'amitriptyline', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d218.s8.e4'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	Warfarin users increased odds ratio gastrointestinal bleeding upon initiation citalopram = NUMBER NUMBER % CI NUMBER - NUMBER fluoxetine = NUMBER NUMBER % CI NUMBER - NUMBER paroxetine = NUMBER NUMBER % CI NUMBER - NUMBER amitriptyline = NUMBER NUMBER % CI NUMBER - NUMBER
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 	paroxetine	amitriptyline	none	{'e1': {'word': 'paroxetine', 'word_index': [(27, 27)], 'id': 'DDI-MedLine.d218.s8.e3'}, 'e2': {'word': 'amitriptyline', 'word_index': [(36, 36)], 'id': 'DDI-MedLine.d218.s8.e4'}, 'sentence_id': 'DDI-MedLine.d218.s8'}	Warfarin users increased odds ratio gastrointestinal bleeding upon initiation citalopram = NUMBER NUMBER % CI NUMBER - NUMBER fluoxetine = NUMBER NUMBER % CI NUMBER - NUMBER paroxetine = NUMBER NUMBER % CI NUMBER - NUMBER amitriptyline = NUMBER NUMBER % CI NUMBER - NUMBER
Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). 	mirtazapine	warfarin	effect	{'e1': {'word': 'mirtazapine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d218.s9.e0'}, 'e2': {'word': 'warfarin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s9.e1'}, 'sentence_id': 'DDI-MedLine.d218.s9'}	Also mirtazapine believed interact warfarin increased risk GI bleeding = NUMBER NUMBER % CI NUMBER - NUMBER
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	citalopram	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'citalopram', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	fluoxetine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'fluoxetine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	paroxetine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'paroxetine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	amitriptyline	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'amitriptyline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	Warfarin	mirtazapine	effect	{'e1': {'word': 'Warfarin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d218.s10.e0'}, 'e2': {'word': 'mirtazapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	citalopram	fluoxetine	none	{'e1': {'word': 'citalopram', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'e2': {'word': 'fluoxetine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	citalopram	paroxetine	none	{'e1': {'word': 'citalopram', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'e2': {'word': 'paroxetine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	citalopram	amitriptyline	none	{'e1': {'word': 'citalopram', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'e2': {'word': 'amitriptyline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	citalopram	mirtazapine	none	{'e1': {'word': 'citalopram', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d218.s10.e1'}, 'e2': {'word': 'mirtazapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	fluoxetine	paroxetine	none	{'e1': {'word': 'fluoxetine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'e2': {'word': 'paroxetine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	fluoxetine	amitriptyline	none	{'e1': {'word': 'fluoxetine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'e2': {'word': 'amitriptyline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	fluoxetine	mirtazapine	none	{'e1': {'word': 'fluoxetine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d218.s10.e2'}, 'e2': {'word': 'mirtazapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	paroxetine	amitriptyline	none	{'e1': {'word': 'paroxetine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'e2': {'word': 'amitriptyline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	paroxetine	mirtazapine	none	{'e1': {'word': 'paroxetine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d218.s10.e3'}, 'e2': {'word': 'mirtazapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 	amitriptyline	mirtazapine	none	{'e1': {'word': 'amitriptyline', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d218.s10.e4'}, 'e2': {'word': 'mirtazapine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d218.s10.e5'}, 'sentence_id': 'DDI-MedLine.d218.s10'}	Warfarin users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding
"Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.
"	cinacalcet	darbepoetin	none	{'e1': {'word': 'cinacalcet', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d166.s0.e0'}, 'e2': {'word': 'darbepoetin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d166.s0.e1'}, 'sentence_id': 'DDI-MedLine.d166.s0'}	Improved parathyroid hormone control cinacalcet associated reduction darbepoetin requirement patients end-stage renal disease .
Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (EPO) resistance. 	erythropoietin	EPO	none	{'e1': {'word': 'erythropoietin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d166.s1.e0'}, 'e2': {'word': 'EPO', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d166.s1.e1'}, 'sentence_id': 'DDI-MedLine.d166.s1'}	Uncontrolled hy per-parathyroidism causes bone marrow fibrosis leading erythropoietin EPO resistance
Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown. 	cinacalcet	darbepoetin	none	{'e1': {'word': 'cinacalcet', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d166.s2.e0'}, 'e2': {'word': 'darbepoetin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d166.s2.e1'}, 'sentence_id': 'DDI-MedLine.d166.s2'}	Medical treatment cinacalcet effective reducing plasma parathyroid hormone PTH levels effect darbepoetin dosing unknown
The primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy. 	darbepoetin	cinacalcet	none	{'e1': {'word': 'darbepoetin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d166.s6.e0'}, 'e2': {'word': 'cinacalcet', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d166.s6.e1'}, 'sentence_id': 'DDI-MedLine.d166.s6'}	primary objective study ascertain difference darbepoetin responsiveness NUMBER months cinacalcet therapy
Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement. 	cinacalcet	darbepoetin	effect	{'e1': {'word': 'cinacalcet', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d166.s17.e0'}, 'e2': {'word': 'darbepoetin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d166.s17.e1'}, 'sentence_id': 'DDI-MedLine.d166.s17'}	Reduction PTH cinacalcet associated decrease darbepoetin requirement
Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.	sunitinib	docetaxel	int	{'e1': {'word': 'sunitinib', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d179.s0.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d179.s0.e1'}, 'sentence_id': 'DDI-MedLine.d179.s0'}	Synergistic interaction sunitinib docetaxel sequence dependent human non-small lung cancer EGFR TKIs resistant mutation
This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.	sunitinib	sunitinib	none	{'e1': {'word': 'sunitinib', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d179.s2.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d179.s2.e1'}, 'sentence_id': 'DDI-MedLine.d179.s2'}	study aimed investigate efficacy single use sunitinib concurrent sequential administration sunitinib docetaxel NSCLC cell lines resistant EGFR TKIs
This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d179.s2.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d179.s2.e2'}, 'sentence_id': 'DDI-MedLine.d179.s2'}	study aimed investigate efficacy single use sunitinib concurrent sequential administration sunitinib docetaxel NSCLC cell lines resistant EGFR TKIs
This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d179.s2.e1'}, 'e2': {'word': 'docetaxel', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d179.s2.e2'}, 'sentence_id': 'DDI-MedLine.d179.s2'}	study aimed investigate efficacy single use sunitinib concurrent sequential administration sunitinib docetaxel NSCLC cell lines resistant EGFR TKIs
NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either sunitinib or docetaxel or both based on various sequential administrations. 	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d179.s3.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d179.s3.e1'}, 'sentence_id': 'DDI-MedLine.d179.s3'}	NSCLC cell lines EGFR T790M mutation K ras mutation exposed either sunitinib docetaxel based various sequential administrations
Sunitinib exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas docetaxel arrested at S phase. 	Sunitinib	docetaxel	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s5.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d179.s5.e1'}, 'sentence_id': 'DDI-MedLine.d179.s5'}	Sunitinib exhibited dose dependent growth inhibition NSCLC cell lines arrested cell cycle G1 phase whereas docetaxel arrested phase
Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. 	sunitinib	docetaxel	effect	{'e1': {'word': 'sunitinib', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d179.s6.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d179.s6.e1'}, 'sentence_id': 'DDI-MedLine.d179.s6'}	Although single concurrent use sunitinib docetaxel anti-proliferative effects sequential administrations drugs remarkably enhanced anti-tumor activity
When cells were exposed to docetaxel followed by sunitinib, synergism was observed. 	docetaxel	sunitinib	effect	{'e1': {'word': 'docetaxel', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d179.s7.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d179.s7.e1'}, 'sentence_id': 'DDI-MedLine.d179.s7'}	cells exposed docetaxel followed sunitinib synergism observed
The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. 	docetaxel	sunitinib	effect	{'e1': {'word': 'docetaxel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d179.s8.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d179.s8.e1'}, 'sentence_id': 'DDI-MedLine.d179.s8'}	molecular basis synergism signaling pathways initially activated docetaxel exposure efficiently suppressed subsequent exposure sunitinib
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	Sunitinib	docetaxel	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s10.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d179.s10.e1'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	Sunitinib single agent exhibits anti-proliferative effects vitro NSCLC cell lines EGFR T790M K ras mutations sequential administration docetaxel followed sunitinib superior sunitinib followed docetaxel concurrent administration
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	Sunitinib	sunitinib	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s10.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d179.s10.e2'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	Sunitinib single agent exhibits anti-proliferative effects vitro NSCLC cell lines EGFR T790M K ras mutations sequential administration docetaxel followed sunitinib superior sunitinib followed docetaxel concurrent administration
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	Sunitinib	sunitinib	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s10.e0'}, 'e2': {'word': 'sunitinib', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d179.s10.e3'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	Sunitinib single agent exhibits anti-proliferative effects vitro NSCLC cell lines EGFR T790M K ras mutations sequential administration docetaxel followed sunitinib superior sunitinib followed docetaxel concurrent administration
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	Sunitinib	docetaxel	none	{'e1': {'word': 'Sunitinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d179.s10.e0'}, 'e2': {'word': 'docetaxel', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d179.s10.e4'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	Sunitinib single agent exhibits anti-proliferative effects vitro NSCLC cell lines EGFR T790M K ras mutations sequential administration docetaxel followed sunitinib superior sunitinib followed docetaxel concurrent administration
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	docetaxel	sunitinib	effect	{'e1': {'word': 'docetaxel', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d179.s10.e1'}, 'e2': {'word': 'sunitinib', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d179.s10.e2'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	Sunitinib single agent exhibits anti-proliferative effects vitro NSCLC cell lines EGFR T790M K ras mutations sequential administration docetaxel followed sunitinib superior sunitinib followed docetaxel concurrent administration
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	docetaxel	sunitinib	none	{'e1': {'word': 'docetaxel', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d179.s10.e1'}, 'e2': {'word': 'sunitinib', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d179.s10.e3'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	Sunitinib single agent exhibits anti-proliferative effects vitro NSCLC cell lines EGFR T790M K ras mutations sequential administration docetaxel followed sunitinib superior sunitinib followed docetaxel concurrent administration
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	docetaxel	docetaxel	none	{'e1': {'word': 'docetaxel', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d179.s10.e1'}, 'e2': {'word': 'docetaxel', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d179.s10.e4'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	Sunitinib single agent exhibits anti-proliferative effects vitro NSCLC cell lines EGFR T790M K ras mutations sequential administration docetaxel followed sunitinib superior sunitinib followed docetaxel concurrent administration
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	sunitinib	none	{'e1': {'word': 'sunitinib', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d179.s10.e2'}, 'e2': {'word': 'sunitinib', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d179.s10.e3'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	Sunitinib single agent exhibits anti-proliferative effects vitro NSCLC cell lines EGFR T790M K ras mutations sequential administration docetaxel followed sunitinib superior sunitinib followed docetaxel concurrent administration
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d179.s10.e2'}, 'e2': {'word': 'docetaxel', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d179.s10.e4'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	Sunitinib single agent exhibits anti-proliferative effects vitro NSCLC cell lines EGFR T790M K ras mutations sequential administration docetaxel followed sunitinib superior sunitinib followed docetaxel concurrent administration
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	sunitinib	docetaxel	none	{'e1': {'word': 'sunitinib', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d179.s10.e3'}, 'e2': {'word': 'docetaxel', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d179.s10.e4'}, 'sentence_id': 'DDI-MedLine.d179.s10'}	Sunitinib single agent exhibits anti-proliferative effects vitro NSCLC cell lines EGFR T790M K ras mutations sequential administration docetaxel followed sunitinib superior sunitinib followed docetaxel concurrent administration
"[Interaction between clopidogrel and proton pump inhibitors].
"	clopidogrel	proton pump inhibitors	none	{'e1': {'word': 'clopidogrel', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d143.s0.e0'}, 'e2': {'word': 'proton pump inhibitors', 'word_index': [(2, 4)], 'id': 'DDI-MedLine.d143.s0.e1'}, 'sentence_id': 'DDI-MedLine.d143.s0'}	Interaction clopidogrel proton pump inhibitors
The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years. 	proton pump inhibitors	clopidogrel	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(2, 4)], 'id': 'DDI-MedLine.d143.s1.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d143.s1.e1'}, 'sentence_id': 'DDI-MedLine.d143.s1'}	drug interaction proton pump inhibitors clopidogrel subject much study recent years
Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature. 	proton pump inhibitors	clopidogrel	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(4, 6)], 'id': 'DDI-MedLine.d143.s2.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d143.s2.e1'}, 'sentence_id': 'DDI-MedLine.d143.s2'}	Contradictory results regarding effect proton pump inhibitors platelet reactivity clinical outcome clopidogrel treated patients reported literature
Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. 	omeprazole	clopidogrel	mechanism	{'e1': {'word': 'omeprazole', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d143.s3.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s3.e1'}, 'sentence_id': 'DDI-MedLine.d143.s3'}	Concomitant use omeprazole clopidogrel found decrease exposure AUC clopidogrel 's active metabolite NUMBER % sharply increase platelet reactivity result inhibition omeprazole CYP2C19 cytochrome P450 CYP enzyme
Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. 	omeprazole	omeprazole	none	{'e1': {'word': 'omeprazole', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d143.s3.e0'}, 'e2': {'word': 'omeprazole', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d143.s3.e2'}, 'sentence_id': 'DDI-MedLine.d143.s3'}	Concomitant use omeprazole clopidogrel found decrease exposure AUC clopidogrel 's active metabolite NUMBER % sharply increase platelet reactivity result inhibition omeprazole CYP2C19 cytochrome P450 CYP enzyme
Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. 	clopidogrel	omeprazole	none	{'e1': {'word': 'clopidogrel', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d143.s3.e1'}, 'e2': {'word': 'omeprazole', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d143.s3.e2'}, 'sentence_id': 'DDI-MedLine.d143.s3'}	Concomitant use omeprazole clopidogrel found decrease exposure AUC clopidogrel 's active metabolite NUMBER % sharply increase platelet reactivity result inhibition omeprazole CYP2C19 cytochrome P450 CYP enzyme
Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use. 	Pantoprazole	clopidogrel	mechanism	{'e1': {'word': 'Pantoprazole', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d143.s4.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d143.s4.e1'}, 'sentence_id': 'DDI-MedLine.d143.s4'}	Pantoprazole much weaker effect clopidogrel 's pharmacokinetics platelet reactivity concomitant use
The influence of the other proton pump inhibitors when used simultaneously with clopidogrel has not yet been investigated in adequately randomized studies. 	proton pump inhibitors	clopidogrel	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d143.s5.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d143.s5.e1'}, 'sentence_id': 'DDI-MedLine.d143.s5'}	influence proton pump inhibitors used simultaneously clopidogrel yet investigated adequately randomized studies
Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. 	clopidogrel	omeprazole	advise	{'e1': {'word': 'clopidogrel', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d143.s6.e0'}, 'e2': {'word': 'omeprazole', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d143.s6.e1'}, 'sentence_id': 'DDI-MedLine.d143.s6'}	Regulatory agencies state combination clopidogrel CYP2C19 inhibitors omeprazole esomeprazole avoided
Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. 	clopidogrel	esomeprazole	advise	{'e1': {'word': 'clopidogrel', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d143.s6.e0'}, 'e2': {'word': 'esomeprazole', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d143.s6.e2'}, 'sentence_id': 'DDI-MedLine.d143.s6'}	Regulatory agencies state combination clopidogrel CYP2C19 inhibitors omeprazole esomeprazole avoided
Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. 	omeprazole	esomeprazole	none	{'e1': {'word': 'omeprazole', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d143.s6.e1'}, 'e2': {'word': 'esomeprazole', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d143.s6.e2'}, 'sentence_id': 'DDI-MedLine.d143.s6'}	Regulatory agencies state combination clopidogrel CYP2C19 inhibitors omeprazole esomeprazole avoided
To date, there is no conclusive evidence of a clinically-relevant interaction between any of the proton pump inhibitors and clopidogrel.	proton pump inhibitors	clopidogrel	none	{'e1': {'word': 'proton pump inhibitors', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d143.s7.e0'}, 'e2': {'word': 'clopidogrel', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d143.s7.e1'}, 'sentence_id': 'DDI-MedLine.d143.s7'}	date conclusive evidence clinically relevant interaction proton pump inhibitors clopidogrel
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	lenalidomide	CCI-779	none	{'e1': {'word': 'lenalidomide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d211.s0.e0'}, 'e2': {'word': 'CCI-779', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d211.s0.e1'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	Phase trial lenalidomide CCI NUMBER patients relapsed multiple myeloma evidence lenalidomide CCI NUMBER interaction via P glycoprotein
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	lenalidomide	lenalidomide	none	{'e1': {'word': 'lenalidomide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d211.s0.e0'}, 'e2': {'word': 'lenalidomide', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d211.s0.e2'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	Phase trial lenalidomide CCI NUMBER patients relapsed multiple myeloma evidence lenalidomide CCI NUMBER interaction via P glycoprotein
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	lenalidomide	CCI-779	none	{'e1': {'word': 'lenalidomide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d211.s0.e0'}, 'e2': {'word': 'CCI-779', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d211.s0.e3'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	Phase trial lenalidomide CCI NUMBER patients relapsed multiple myeloma evidence lenalidomide CCI NUMBER interaction via P glycoprotein
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	CCI-779	lenalidomide	none	{'e1': {'word': 'CCI-779', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d211.s0.e1'}, 'e2': {'word': 'lenalidomide', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d211.s0.e2'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	Phase trial lenalidomide CCI NUMBER patients relapsed multiple myeloma evidence lenalidomide CCI NUMBER interaction via P glycoprotein
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	CCI-779	CCI-779	none	{'e1': {'word': 'CCI-779', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d211.s0.e1'}, 'e2': {'word': 'CCI-779', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d211.s0.e3'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	Phase trial lenalidomide CCI NUMBER patients relapsed multiple myeloma evidence lenalidomide CCI NUMBER interaction via P glycoprotein
"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
"	lenalidomide	CCI-779	none	{'e1': {'word': 'lenalidomide', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d211.s0.e2'}, 'e2': {'word': 'CCI-779', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d211.s0.e3'}, 'sentence_id': 'DDI-MedLine.d211.s0'}	Phase trial lenalidomide CCI NUMBER patients relapsed multiple myeloma evidence lenalidomide CCI NUMBER interaction via P glycoprotein
The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.	lenalidomide	CCI-779	effect	{'e1': {'word': 'lenalidomide', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d211.s2.e0'}, 'e2': {'word': 'CCI-779', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d211.s2.e1'}, 'sentence_id': 'DDI-MedLine.d211.s2'}	preclinical combination lenalidomide mTOR inhibitor CCI NUMBER displayed synergy vitro represents novel combination MM
"The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
"	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d194.s0.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d194.s0.e1'}, 'sentence_id': 'DDI-MedLine.d194.s0'}	role p27 Kip1 dasatinib enhanced paclitaxel cytotoxicity human ovarian cancer cells
The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d194.s4.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d194.s4.e1'}, 'sentence_id': 'DDI-MedLine.d194.s4'}	effect dasatinib inhibitor Src Abl kinases paclitaxel sensitivity measured ovarian cancer cells HEY xenografts
The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d194.s5.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d194.s5.e1'}, 'sentence_id': 'DDI-MedLine.d194.s5'}	roles p27 Kip1 Bcl NUMBER Cdk1 apoptosis induced dasatinib paclitaxel assessed using terminal deoxynucleotidyl transferase mediated dUTP nick end labeling TUNEL assay siRNA knockdown gene expression transfection Bcl NUMBER Cdk1 expression vectors flow cytometry
HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. 	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d194.s9.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d194.s9.e1'}, 'sentence_id': 'DDI-MedLine.d194.s9'}	HEY cells treated dasatinib plus paclitaxel formed fewer colonies cells treated either agent alone
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d194.s10.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d194.s10.e1'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment HEY xenograft bearing mice dasatinib plus paclitaxel inhibited tumor growth treatment either agent alone average tumor volume per mouse dasatinib + paclitaxel vs paclitaxel NUMBER vs NUMBER cm3 difference = NUMBER cm3 NUMBER % confidence interval CI = NUMBER NUMBER cm3 P = NUMBER
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	dasatinib	none	{'e1': {'word': 'dasatinib', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d194.s10.e0'}, 'e2': {'word': 'dasatinib', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d194.s10.e2'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment HEY xenograft bearing mice dasatinib plus paclitaxel inhibited tumor growth treatment either agent alone average tumor volume per mouse dasatinib + paclitaxel vs paclitaxel NUMBER vs NUMBER cm3 difference = NUMBER cm3 NUMBER % confidence interval CI = NUMBER NUMBER cm3 P = NUMBER
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d194.s10.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d194.s10.e3'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment HEY xenograft bearing mice dasatinib plus paclitaxel inhibited tumor growth treatment either agent alone average tumor volume per mouse dasatinib + paclitaxel vs paclitaxel NUMBER vs NUMBER cm3 difference = NUMBER cm3 NUMBER % confidence interval CI = NUMBER NUMBER cm3 P = NUMBER
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d194.s10.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d194.s10.e4'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment HEY xenograft bearing mice dasatinib plus paclitaxel inhibited tumor growth treatment either agent alone average tumor volume per mouse dasatinib + paclitaxel vs paclitaxel NUMBER vs NUMBER cm3 difference = NUMBER cm3 NUMBER % confidence interval CI = NUMBER NUMBER cm3 P = NUMBER
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	paclitaxel	dasatinib	none	{'e1': {'word': 'paclitaxel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d194.s10.e1'}, 'e2': {'word': 'dasatinib', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d194.s10.e2'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment HEY xenograft bearing mice dasatinib plus paclitaxel inhibited tumor growth treatment either agent alone average tumor volume per mouse dasatinib + paclitaxel vs paclitaxel NUMBER vs NUMBER cm3 difference = NUMBER cm3 NUMBER % confidence interval CI = NUMBER NUMBER cm3 P = NUMBER
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	paclitaxel	paclitaxel	none	{'e1': {'word': 'paclitaxel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d194.s10.e1'}, 'e2': {'word': 'paclitaxel', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d194.s10.e3'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment HEY xenograft bearing mice dasatinib plus paclitaxel inhibited tumor growth treatment either agent alone average tumor volume per mouse dasatinib + paclitaxel vs paclitaxel NUMBER vs NUMBER cm3 difference = NUMBER cm3 NUMBER % confidence interval CI = NUMBER NUMBER cm3 P = NUMBER
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	paclitaxel	paclitaxel	none	{'e1': {'word': 'paclitaxel', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d194.s10.e1'}, 'e2': {'word': 'paclitaxel', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d194.s10.e4'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment HEY xenograft bearing mice dasatinib plus paclitaxel inhibited tumor growth treatment either agent alone average tumor volume per mouse dasatinib + paclitaxel vs paclitaxel NUMBER vs NUMBER cm3 difference = NUMBER cm3 NUMBER % confidence interval CI = NUMBER NUMBER cm3 P = NUMBER
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d194.s10.e2'}, 'e2': {'word': 'paclitaxel', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d194.s10.e3'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment HEY xenograft bearing mice dasatinib plus paclitaxel inhibited tumor growth treatment either agent alone average tumor volume per mouse dasatinib + paclitaxel vs paclitaxel NUMBER vs NUMBER cm3 difference = NUMBER cm3 NUMBER % confidence interval CI = NUMBER NUMBER cm3 P = NUMBER
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d194.s10.e2'}, 'e2': {'word': 'paclitaxel', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d194.s10.e4'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment HEY xenograft bearing mice dasatinib plus paclitaxel inhibited tumor growth treatment either agent alone average tumor volume per mouse dasatinib + paclitaxel vs paclitaxel NUMBER vs NUMBER cm3 difference = NUMBER cm3 NUMBER % confidence interval CI = NUMBER NUMBER cm3 P = NUMBER
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 	paclitaxel	paclitaxel	none	{'e1': {'word': 'paclitaxel', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d194.s10.e3'}, 'e2': {'word': 'paclitaxel', 'word_index': [(24, 24)], 'id': 'DDI-MedLine.d194.s10.e4'}, 'sentence_id': 'DDI-MedLine.d194.s10'}	Treatment HEY xenograft bearing mice dasatinib plus paclitaxel inhibited tumor growth treatment either agent alone average tumor volume per mouse dasatinib + paclitaxel vs paclitaxel NUMBER vs NUMBER cm3 difference = NUMBER cm3 NUMBER % confidence interval CI = NUMBER NUMBER cm3 P = NUMBER
dasatinib + paclitaxel vs. 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d194.s11.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d194.s11.e1'}, 'sentence_id': 'DDI-MedLine.d194.s11'}	dasatinib + paclitaxel vs.
The siRNA knockdown of p27(Kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). 	dasatinib	paclitaxel	none	{'e1': {'word': 'dasatinib', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d194.s15.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d194.s15.e1'}, 'sentence_id': 'DDI-MedLine.d194.s15'}	siRNA knockdown p27 Kip1 decreased dasatinib paclitaxel induced apoptosis compared negative control siRNA sub-G1 fraction control siRNA vs. p27 Kip1 siRNA NUMBER % vs. NUMBER % difference = NUMBER % NUMBER % CI = NUMBER % NUMBER % P = NUMBER
Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. 	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d194.s16.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d194.s16.e1'}, 'sentence_id': 'DDI-MedLine.d194.s16'}	Studies forced expression siRNA knockdown Bcl NUMBER Cdk1 suggest dasatinib mediated induction p27 Kip1 enhanced paclitaxel induced apoptosis negatively regulating Bcl NUMBER Cdk1 expression
Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.	dasatinib	paclitaxel	effect	{'e1': {'word': 'dasatinib', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d194.s17.e0'}, 'e2': {'word': 'paclitaxel', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d194.s17.e1'}, 'sentence_id': 'DDI-MedLine.d194.s17'}	Inhibition Src family Abl kinases either siRNAs dasatinib enhances paclitaxel sensitivity ovarian cancer cells p27 Kip1 mediated suppression Bcl NUMBER Cdk1 expression
[Efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease]	amlodipine	valsartan	none	{'e1': {'word': 'amlodipine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d200.s0.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d200.s0.e1'}, 'sentence_id': 'DDI-MedLine.d200.s0'}	Efficacy fixed combination amlodipine valsartan hospitalized patients hypertensive disease
Efficacy and tolerability of fixed amlodipine/valsartan combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. 	amlodipine	valsartan	none	{'e1': {'word': 'amlodipine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d200.s1.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d200.s1.e1'}, 'sentence_id': 'DDI-MedLine.d200.s1'}	Efficacy tolerability fixed amlodipine valsartan combination studied NUMBER patients hypertensive disease hospitalized departments general internal medicine cardiology
All patients had indications for antihypertensive therapy and were randomized either to fixed combination amlodipine/valsartan (n=43) or to therapy which corresponded to the hospital formulary (n=43). 	amlodipine	valsartan	none	{'e1': {'word': 'amlodipine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d200.s2.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d200.s2.e1'}, 'sentence_id': 'DDI-MedLine.d200.s2'}	patients indications antihypertensive therapy randomized either fixed combination amlodipine valsartan n = NUMBER therapy corresponded hospital formulary n = NUMBER
Rate of achievement of target BP with fixed combination amlodipine/valsartan (93%) was comparable with that on traditional therapy (90%). 	amlodipine	valsartan	none	{'e1': {'word': 'amlodipine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d200.s7.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d200.s7.e1'}, 'sentence_id': 'DDI-MedLine.d200.s7'}	Rate achievement target BP fixed combination amlodipine valsartan NUMBER % comparable traditional therapy NUMBER %
But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). 	amlodipine	valsartan	effect	{'e1': {'word': 'amlodipine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d200.s8.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d200.s8.e1'}, 'sentence_id': 'DDI-MedLine.d200.s8'}	use fixed combination amlodipine valsartan compared traditional therapy associated lower clinical self measured BP quicker achievement target BP NUMBER + - NUMBER NUMBER + - NUMBER days respectively NUMBER lesser number antihypertensive drugs NUMBER + - NUMBER NUMBER + - NUMBER days respectively lower rate concealed inefficacy treatment NUMBER NUMBER % respectively NUMBER
But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). 	amlodipine	antihypertensive drugs	none	{'e1': {'word': 'amlodipine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d200.s8.e0'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(31, 32)], 'id': 'DDI-MedLine.d200.s8.e2'}, 'sentence_id': 'DDI-MedLine.d200.s8'}	use fixed combination amlodipine valsartan compared traditional therapy associated lower clinical self measured BP quicker achievement target BP NUMBER + - NUMBER NUMBER + - NUMBER days respectively NUMBER lesser number antihypertensive drugs NUMBER + - NUMBER NUMBER + - NUMBER days respectively lower rate concealed inefficacy treatment NUMBER NUMBER % respectively NUMBER
But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). 	valsartan	antihypertensive drugs	none	{'e1': {'word': 'valsartan', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d200.s8.e1'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(31, 32)], 'id': 'DDI-MedLine.d200.s8.e2'}, 'sentence_id': 'DDI-MedLine.d200.s8'}	use fixed combination amlodipine valsartan compared traditional therapy associated lower clinical self measured BP quicker achievement target BP NUMBER + - NUMBER NUMBER + - NUMBER days respectively NUMBER lesser number antihypertensive drugs NUMBER + - NUMBER NUMBER + - NUMBER days respectively lower rate concealed inefficacy treatment NUMBER NUMBER % respectively NUMBER
We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	amlodipine	valsartan	effect	{'e1': {'word': 'amlodipine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d200.s10.e0'}, 'e2': {'word': 'valsartan', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d200.s10.e1'}, 'sentence_id': 'DDI-MedLine.d200.s10'}	demonstrated appropriateness inhospital administration fixed amlodipine valsartan combination approach allowing achieve target BP shorter time use fewer antihypertensive drugs diminishing concealed inefficacy treatment
We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	amlodipine	antihypertensive drugs	none	{'e1': {'word': 'amlodipine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d200.s10.e0'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d200.s10.e2'}, 'sentence_id': 'DDI-MedLine.d200.s10'}	demonstrated appropriateness inhospital administration fixed amlodipine valsartan combination approach allowing achieve target BP shorter time use fewer antihypertensive drugs diminishing concealed inefficacy treatment
We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	valsartan	antihypertensive drugs	none	{'e1': {'word': 'valsartan', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d200.s10.e1'}, 'e2': {'word': 'antihypertensive drugs', 'word_index': [(17, 18)], 'id': 'DDI-MedLine.d200.s10.e2'}, 'sentence_id': 'DDI-MedLine.d200.s10'}	demonstrated appropriateness inhospital administration fixed amlodipine valsartan combination approach allowing achieve target BP shorter time use fewer antihypertensive drugs diminishing concealed inefficacy treatment
The incubations were performed in the absence and presence of the non-specific CYP inhibitor, 1-aminobenzotriazole (ABT) and isoform-specific inhibitors. 	1-aminobenzotriazole	ABT	none	{'e1': {'word': '1-aminobenzotriazole', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d189.s3.e0'}, 'e2': {'word': 'ABT', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d189.s3.e1'}, 'sentence_id': 'DDI-MedLine.d189.s3'}	incubations performed absence presence non-specific CYP inhibitor NUMBER aminobenzotriazole ABT isoform specific inhibitors
ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. 	ABT	precocene I	effect	{'e1': {'word': 'ABT', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s7.e0'}, 'e2': {'word': 'precocene I', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d189.s7.e1'}, 'sentence_id': 'DDI-MedLine.d189.s7'}	ABT decreased toxicity precocene increased exposure parent compound decreased metabolite levels dose dependent manner
Of the isoform-specific CYP inhibitors tested for an effect on the precocene I metabolite profile, only tranylcypromine was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. 	precocene I	tranylcypromine	none	{'e1': {'word': 'precocene I', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s8.e0'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d189.s8.e1'}, 'sentence_id': 'DDI-MedLine.d189.s8'}	isoform specific CYP inhibitors tested effect precocene metabolite profile tranylcypromine noticeably effective indicating role CYPs 2A6 2C9 2Cl9 2E1
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	ABT	diethyldithiocarbamate	none	{'e1': {'word': 'ABT', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s9.e0'}, 'e2': {'word': 'diethyldithiocarbamate', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d189.s9.e1'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	respect toxicity order CYP inhibitor effectiveness ABT > diethyldithiocarbamate ~ tranylcypromine > ketoconazole
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	ABT	tranylcypromine	none	{'e1': {'word': 'ABT', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s9.e0'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d189.s9.e2'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	respect toxicity order CYP inhibitor effectiveness ABT > diethyldithiocarbamate ~ tranylcypromine > ketoconazole
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	ABT	ketoconazole	none	{'e1': {'word': 'ABT', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s9.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d189.s9.e3'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	respect toxicity order CYP inhibitor effectiveness ABT > diethyldithiocarbamate ~ tranylcypromine > ketoconazole
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	diethyldithiocarbamate	tranylcypromine	none	{'e1': {'word': 'diethyldithiocarbamate', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d189.s9.e1'}, 'e2': {'word': 'tranylcypromine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d189.s9.e2'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	respect toxicity order CYP inhibitor effectiveness ABT > diethyldithiocarbamate ~ tranylcypromine > ketoconazole
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	diethyldithiocarbamate	ketoconazole	none	{'e1': {'word': 'diethyldithiocarbamate', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d189.s9.e1'}, 'e2': {'word': 'ketoconazole', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d189.s9.e3'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	respect toxicity order CYP inhibitor effectiveness ABT > diethyldithiocarbamate ~ tranylcypromine > ketoconazole
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. 	tranylcypromine	ketoconazole	none	{'e1': {'word': 'tranylcypromine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d189.s9.e2'}, 'e2': {'word': 'ketoconazole', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d189.s9.e3'}, 'sentence_id': 'DDI-MedLine.d189.s9'}	respect toxicity order CYP inhibitor effectiveness ABT > diethyldithiocarbamate ~ tranylcypromine > ketoconazole
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	Furafylline	sulfaphenazole	none	{'e1': {'word': 'Furafylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e0'}, 'e2': {'word': 'sulfaphenazole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d189.s10.e1'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	Furafylline sulfaphenazole effect quinidine appeared augment precocene toxicity
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	Furafylline	quinidine	none	{'e1': {'word': 'Furafylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e0'}, 'e2': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d189.s10.e2'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	Furafylline sulfaphenazole effect quinidine appeared augment precocene toxicity
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	Furafylline	precocene I	none	{'e1': {'word': 'Furafylline', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d189.s10.e0'}, 'e2': {'word': 'precocene I', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s10.e3'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	Furafylline sulfaphenazole effect quinidine appeared augment precocene toxicity
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	sulfaphenazole	quinidine	none	{'e1': {'word': 'sulfaphenazole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d189.s10.e1'}, 'e2': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d189.s10.e2'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	Furafylline sulfaphenazole effect quinidine appeared augment precocene toxicity
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	sulfaphenazole	precocene I	none	{'e1': {'word': 'sulfaphenazole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d189.s10.e1'}, 'e2': {'word': 'precocene I', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s10.e3'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	Furafylline sulfaphenazole effect quinidine appeared augment precocene toxicity
Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. 	quinidine	precocene I	effect	{'e1': {'word': 'quinidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d189.s10.e2'}, 'e2': {'word': 'precocene I', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d189.s10.e3'}, 'sentence_id': 'DDI-MedLine.d189.s10'}	Furafylline sulfaphenazole effect quinidine appeared augment precocene toxicity
These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of precocene I and therefore may not be an appropriate model for precocene I metabolism. 	precocene I	precocene I	none	{'e1': {'word': 'precocene I', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d189.s11.e0'}, 'e2': {'word': 'precocene I', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d189.s11.e1'}, 'sentence_id': 'DDI-MedLine.d189.s11'}	results suggest rat liver slices reproduce reported vivo biotransformation precocene therefore may appropriate model precocene metabolism
Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.	Calcium	nonheme iron	none	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s0.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(5, 5), (8, 8)], 'id': 'DDI-MedLine.d169.s0.e1'}, 'sentence_id': 'DDI-MedLine.d169.s0'}	Calcium inhibit absorption NUMBER milligrams nonheme heme iron iron doses less NUMBER milligrams nonpregnant women
Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.	Calcium	heme iron	none	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s0.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d169.s0.e2'}, 'sentence_id': 'DDI-MedLine.d169.s0'}	Calcium inhibit absorption NUMBER milligrams nonheme heme iron iron doses less NUMBER milligrams nonpregnant women
Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.	nonheme iron	heme iron	none	{'e1': {'word': 'nonheme iron', 'word_index': [(5, 5), (8, 8)], 'id': 'DDI-MedLine.d169.s0.e1'}, 'e2': {'word': 'heme iron', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d169.s0.e2'}, 'sentence_id': 'DDI-MedLine.d169.s0'}	Calcium inhibit absorption NUMBER milligrams nonheme heme iron iron doses less NUMBER milligrams nonpregnant women
Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. 	Calcium	nonheme iron	mechanism	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s1.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(7, 7), (10, 10)], 'id': 'DDI-MedLine.d169.s1.e1'}, 'sentence_id': 'DDI-MedLine.d169.s1'}	Calcium known component diet may affect absorption nonheme heme iron iron
Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. 	Calcium	heme iron	mechanism	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s1.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d169.s1.e2'}, 'sentence_id': 'DDI-MedLine.d169.s1'}	Calcium known component diet may affect absorption nonheme heme iron iron
Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. 	nonheme iron	heme iron	none	{'e1': {'word': 'nonheme iron', 'word_index': [(7, 7), (10, 10)], 'id': 'DDI-MedLine.d169.s1.e1'}, 'e2': {'word': 'heme iron', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d169.s1.e2'}, 'sentence_id': 'DDI-MedLine.d169.s1'}	Calcium known component diet may affect absorption nonheme heme iron iron
However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. 	calcium	iron	mechanism	{'e1': {'word': 'calcium', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d169.s2.e0'}, 'e2': {'word': 'iron', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d169.s2.e1'}, 'sentence_id': 'DDI-MedLine.d169.s2'}	However evidence calcium effect iron absorption mainly comes studies isolate effect calcium dietary components detected single meal studies
However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. 	calcium	calcium	none	{'e1': {'word': 'calcium', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d169.s2.e0'}, 'e2': {'word': 'calcium', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d169.s2.e2'}, 'sentence_id': 'DDI-MedLine.d169.s2'}	However evidence calcium effect iron absorption mainly comes studies isolate effect calcium dietary components detected single meal studies
However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. 	iron	calcium	none	{'e1': {'word': 'iron', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d169.s2.e1'}, 'e2': {'word': 'calcium', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d169.s2.e2'}, 'sentence_id': 'DDI-MedLine.d169.s2'}	However evidence calcium effect iron absorption mainly comes studies isolate effect calcium dietary components detected single meal studies
Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. 	calcium	nonheme iron	none	{'e1': {'word': 'calcium', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d169.s3.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(6, 6), (9, 9)], 'id': 'DDI-MedLine.d169.s3.e1'}, 'sentence_id': 'DDI-MedLine.d169.s3'}	objective establish potential effects calcium absorption nonheme heme iron iron dose response effect absence meal
Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. 	calcium	heme iron	none	{'e1': {'word': 'calcium', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d169.s3.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d169.s3.e2'}, 'sentence_id': 'DDI-MedLine.d169.s3'}	objective establish potential effects calcium absorption nonheme heme iron iron dose response effect absence meal
Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. 	nonheme iron	heme iron	none	{'e1': {'word': 'nonheme iron', 'word_index': [(6, 6), (9, 9)], 'id': 'DDI-MedLine.d169.s3.e1'}, 'e2': {'word': 'heme iron', 'word_index': [(7, 8)], 'id': 'DDI-MedLine.d169.s3.e2'}, 'sentence_id': 'DDI-MedLine.d169.s3'}	objective establish potential effects calcium absorption nonheme heme iron iron dose response effect absence meal
We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). 	calcium	nonheme iron	none	{'e1': {'word': 'calcium', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d169.s5.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d169.s5.e1'}, 'sentence_id': 'DDI-MedLine.d169.s5'}	evaluated effects calcium doses NUMBER NUMBER mg absorption NUMBER mg nonheme iron ferrous sulfate
We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). 	calcium	ferrous sulfate	none	{'e1': {'word': 'calcium', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d169.s5.e0'}, 'e2': {'word': 'ferrous sulfate', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d169.s5.e2'}, 'sentence_id': 'DDI-MedLine.d169.s5'}	evaluated effects calcium doses NUMBER NUMBER mg absorption NUMBER mg nonheme iron ferrous sulfate
We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). 	nonheme iron	ferrous sulfate	none	{'e1': {'word': 'nonheme iron', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d169.s5.e1'}, 'e2': {'word': 'ferrous sulfate', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d169.s5.e2'}, 'sentence_id': 'DDI-MedLine.d169.s5'}	evaluated effects calcium doses NUMBER NUMBER mg absorption NUMBER mg nonheme iron ferrous sulfate
We also evaluated the effects of calcium doses between 200 and 800 mg on absorption of 5 mg heme iron [as concentrated RBC (CRBC)]. 	calcium	heme iron	none	{'e1': {'word': 'calcium', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d169.s6.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d169.s6.e1'}, 'sentence_id': 'DDI-MedLine.d169.s6'}	also evaluated effects calcium doses NUMBER NUMBER mg absorption NUMBER mg heme iron concentrated RBC CRBC
Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. 	Calcium	calcium chloride	none	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s7.e0'}, 'e2': {'word': 'calcium chloride', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d169.s7.e1'}, 'sentence_id': 'DDI-MedLine.d169.s7'}	Calcium administered calcium chloride studies minerals ingested empty stomach
Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. 	Calcium	minerals	none	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s7.e0'}, 'e2': {'word': 'minerals', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d169.s7.e2'}, 'sentence_id': 'DDI-MedLine.d169.s7'}	Calcium administered calcium chloride studies minerals ingested empty stomach
Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. 	calcium chloride	minerals	none	{'e1': {'word': 'calcium chloride', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d169.s7.e1'}, 'e2': {'word': 'minerals', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d169.s7.e2'}, 'sentence_id': 'DDI-MedLine.d169.s7'}	Calcium administered calcium chloride studies minerals ingested empty stomach
Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.	Calcium	nonheme iron	mechanism	{'e1': {'word': 'Calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s8.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(5, 6)], 'id': 'DDI-MedLine.d169.s8.e1'}, 'sentence_id': 'DDI-MedLine.d169.s8'}	Calcium doses NUMBER mg diminished nonheme iron absorption average NUMBER %
A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%. 	calcium	heme iron	mechanism	{'e1': {'word': 'calcium', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d169.s9.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(8, 9)], 'id': 'DDI-MedLine.d169.s9.e1'}, 'sentence_id': 'DDI-MedLine.d169.s9'}	calcium dose NUMBER mg diminished absorption NUMBER mg heme iron NUMBER %
In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. 	calcium	nonheme iron	mechanism	{'e1': {'word': 'calcium', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d169.s10.e0'}, 'e2': {'word': 'nonheme iron', 'word_index': [(11, 11), (15, 15)], 'id': 'DDI-MedLine.d169.s10.e1'}, 'sentence_id': 'DDI-MedLine.d169.s10'}	conclusion demonstrated isolated effect calcium chloride absorption NUMBER mg iron provided nonheme sulfate heme CRBC iron
In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. 	calcium	heme iron	mechanism	{'e1': {'word': 'calcium', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d169.s10.e0'}, 'e2': {'word': 'heme iron', 'word_index': [(13, 13), (15, 15)], 'id': 'DDI-MedLine.d169.s10.e2'}, 'sentence_id': 'DDI-MedLine.d169.s10'}	conclusion demonstrated isolated effect calcium chloride absorption NUMBER mg iron provided nonheme sulfate heme CRBC iron
In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. 	nonheme iron	heme iron	none	{'e1': {'word': 'nonheme iron', 'word_index': [(11, 11), (15, 15)], 'id': 'DDI-MedLine.d169.s10.e1'}, 'e2': {'word': 'heme iron', 'word_index': [(13, 13), (15, 15)], 'id': 'DDI-MedLine.d169.s10.e2'}, 'sentence_id': 'DDI-MedLine.d169.s10'}	conclusion demonstrated isolated effect calcium chloride absorption NUMBER mg iron provided nonheme sulfate heme CRBC iron
"Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.
"	Ephedrine	dexmedetomidine	effect	{'e1': {'word': 'Ephedrine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d227.s0.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d227.s0.e1'}, 'sentence_id': 'DDI-MedLine.d227.s0'}	Ephedrine enhances antinociceptive effect dexmedetomidine mice
The purpose of this study was to evaluate whether the psychostimulant drug ephedrine has any effect on dexmedetomidine-induced antinociception and locomotor inhibitor activity in mice in acute application.	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d227.s2.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d227.s2.e1'}, 'sentence_id': 'DDI-MedLine.d227.s2'}	purpose study evaluate whether psychostimulant drug ephedrine effect dexmedetomidine induced antinociception locomotor inhibitor activity mice acute application
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d227.s6.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s6.e1'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	saline + saline ephedrine NUMBER mg / kg + saline saline + dexmedetomidine NUMBER g / kg ephedrine NUMBER mg / kg + dexmedetomidine NUMBER g / kg intraperitoneally NUMBER min hot plate holed open field tests
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	ephedrine	ephedrine	none	{'e1': {'word': 'ephedrine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d227.s6.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d227.s6.e2'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	saline + saline ephedrine NUMBER mg / kg + saline saline + dexmedetomidine NUMBER g / kg ephedrine NUMBER mg / kg + dexmedetomidine NUMBER g / kg intraperitoneally NUMBER min hot plate holed open field tests
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d227.s6.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d227.s6.e3'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	saline + saline ephedrine NUMBER mg / kg + saline saline + dexmedetomidine NUMBER g / kg ephedrine NUMBER mg / kg + dexmedetomidine NUMBER g / kg intraperitoneally NUMBER min hot plate holed open field tests
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	dexmedetomidine	ephedrine	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s6.e1'}, 'e2': {'word': 'ephedrine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d227.s6.e2'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	saline + saline ephedrine NUMBER mg / kg + saline saline + dexmedetomidine NUMBER g / kg ephedrine NUMBER mg / kg + dexmedetomidine NUMBER g / kg intraperitoneally NUMBER min hot plate holed open field tests
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	dexmedetomidine	dexmedetomidine	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d227.s6.e1'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d227.s6.e3'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	saline + saline ephedrine NUMBER mg / kg + saline saline + dexmedetomidine NUMBER g / kg ephedrine NUMBER mg / kg + dexmedetomidine NUMBER g / kg intraperitoneally NUMBER min hot plate holed open field tests
saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d227.s6.e2'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(23, 23)], 'id': 'DDI-MedLine.d227.s6.e3'}, 'sentence_id': 'DDI-MedLine.d227.s6'}	saline + saline ephedrine NUMBER mg / kg + saline saline + dexmedetomidine NUMBER g / kg ephedrine NUMBER mg / kg + dexmedetomidine NUMBER g / kg intraperitoneally NUMBER min hot plate holed open field tests
In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. 	dexmedetomidine	ephedrine	effect	{'e1': {'word': 'dexmedetomidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d227.s7.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d227.s7.e1'}, 'sentence_id': 'DDI-MedLine.d227.s7'}	hot plate test mice co-administration NUMBER g / kg dexmedetomidine NUMBER mg / kg ephedrine intraperitoneally enhanced also prolonged duration antinociception induced dexmedetomidine
In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. 	dexmedetomidine	dexmedetomidine	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d227.s7.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d227.s7.e2'}, 'sentence_id': 'DDI-MedLine.d227.s7'}	hot plate test mice co-administration NUMBER g / kg dexmedetomidine NUMBER mg / kg ephedrine intraperitoneally enhanced also prolonged duration antinociception induced dexmedetomidine
In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. 	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d227.s7.e1'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d227.s7.e2'}, 'sentence_id': 'DDI-MedLine.d227.s7'}	hot plate test mice co-administration NUMBER g / kg dexmedetomidine NUMBER mg / kg ephedrine intraperitoneally enhanced also prolonged duration antinociception induced dexmedetomidine
At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. 	dexmedetomidine	ephedrine	effect	{'e1': {'word': 'dexmedetomidine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d227.s8.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d227.s8.e1'}, 'sentence_id': 'DDI-MedLine.d227.s8'}	time locomotor inhibitory effect dexmedetomidine counteracted ephedrine
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	ephedrine	effect	{'e1': {'word': 'dexmedetomidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d227.s9.e0'}, 'e2': {'word': 'ephedrine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d227.s9.e1'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	concluded combined administration dexmedetomidine ephedrine may beneficial effects treatment pain without causing sedation limits use dexmedetomidine analgesic humans
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	dexmedetomidine	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d227.s9.e0'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d227.s9.e2'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	concluded combined administration dexmedetomidine ephedrine may beneficial effects treatment pain without causing sedation limits use dexmedetomidine analgesic humans
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	analgesic	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d227.s9.e0'}, 'e2': {'word': 'analgesic', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d227.s9.e3'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	concluded combined administration dexmedetomidine ephedrine may beneficial effects treatment pain without causing sedation limits use dexmedetomidine analgesic humans
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	ephedrine	dexmedetomidine	none	{'e1': {'word': 'ephedrine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d227.s9.e1'}, 'e2': {'word': 'dexmedetomidine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d227.s9.e2'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	concluded combined administration dexmedetomidine ephedrine may beneficial effects treatment pain without causing sedation limits use dexmedetomidine analgesic humans
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	ephedrine	analgesic	none	{'e1': {'word': 'ephedrine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d227.s9.e1'}, 'e2': {'word': 'analgesic', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d227.s9.e3'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	concluded combined administration dexmedetomidine ephedrine may beneficial effects treatment pain without causing sedation limits use dexmedetomidine analgesic humans
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	dexmedetomidine	analgesic	none	{'e1': {'word': 'dexmedetomidine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d227.s9.e2'}, 'e2': {'word': 'analgesic', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d227.s9.e3'}, 'sentence_id': 'DDI-MedLine.d227.s9'}	concluded combined administration dexmedetomidine ephedrine may beneficial effects treatment pain without causing sedation limits use dexmedetomidine analgesic humans
"Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
"	Lapatinib	herceptin	effect	{'e1': {'word': 'Lapatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s0.e0'}, 'e2': {'word': 'herceptin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d164.s0.e1'}, 'sentence_id': 'DDI-MedLine.d164.s0'}	Lapatinib enhances herceptin mediated antibody dependent cellular cytotoxicity regulation cell surface HER2 expression
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	Herceptin	effect	{'e1': {'word': 'lapatinib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d164.s1.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d164.s1.e1'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	Although previously reported lapatinib combined Herceptin improved progression free survival rate compared lapatinib alone patients Herceptin refractory HER2 positive metastatic breast cancer mechanism purported antiproliferative effect relating synergism NUMBER agents
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	lapatinib	none	{'e1': {'word': 'lapatinib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d164.s1.e0'}, 'e2': {'word': 'lapatinib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d164.s1.e2'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	Although previously reported lapatinib combined Herceptin improved progression free survival rate compared lapatinib alone patients Herceptin refractory HER2 positive metastatic breast cancer mechanism purported antiproliferative effect relating synergism NUMBER agents
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	Herceptin	none	{'e1': {'word': 'lapatinib', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d164.s1.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d164.s1.e3'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	Although previously reported lapatinib combined Herceptin improved progression free survival rate compared lapatinib alone patients Herceptin refractory HER2 positive metastatic breast cancer mechanism purported antiproliferative effect relating synergism NUMBER agents
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	Herceptin	lapatinib	none	{'e1': {'word': 'Herceptin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d164.s1.e1'}, 'e2': {'word': 'lapatinib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d164.s1.e2'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	Although previously reported lapatinib combined Herceptin improved progression free survival rate compared lapatinib alone patients Herceptin refractory HER2 positive metastatic breast cancer mechanism purported antiproliferative effect relating synergism NUMBER agents
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	Herceptin	Herceptin	none	{'e1': {'word': 'Herceptin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d164.s1.e1'}, 'e2': {'word': 'Herceptin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d164.s1.e3'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	Although previously reported lapatinib combined Herceptin improved progression free survival rate compared lapatinib alone patients Herceptin refractory HER2 positive metastatic breast cancer mechanism purported antiproliferative effect relating synergism NUMBER agents
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	lapatinib	Herceptin	none	{'e1': {'word': 'lapatinib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d164.s1.e2'}, 'e2': {'word': 'Herceptin', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d164.s1.e3'}, 'sentence_id': 'DDI-MedLine.d164.s1'}	Although previously reported lapatinib combined Herceptin improved progression free survival rate compared lapatinib alone patients Herceptin refractory HER2 positive metastatic breast cancer mechanism purported antiproliferative effect relating synergism NUMBER agents
We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). 	lapatinib	Herceptin	none	{'e1': {'word': 'lapatinib', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d164.s2.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d164.s2.e1'}, 'sentence_id': 'DDI-MedLine.d164.s2'}	evaluated lapatinib interacts Herceptin HER2 positive breast cancer particular focus Herceptin mediated antibody dependent cellular cytotoxicity ADCC
We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). 	lapatinib	Herceptin	none	{'e1': {'word': 'lapatinib', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d164.s2.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d164.s2.e2'}, 'sentence_id': 'DDI-MedLine.d164.s2'}	evaluated lapatinib interacts Herceptin HER2 positive breast cancer particular focus Herceptin mediated antibody dependent cellular cytotoxicity ADCC
We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). 	Herceptin	Herceptin	none	{'e1': {'word': 'Herceptin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d164.s2.e1'}, 'e2': {'word': 'Herceptin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d164.s2.e2'}, 'sentence_id': 'DDI-MedLine.d164.s2'}	evaluated lapatinib interacts Herceptin HER2 positive breast cancer particular focus Herceptin mediated antibody dependent cellular cytotoxicity ADCC
In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC. 	lapatinib	Herceptin	effect	{'e1': {'word': 'lapatinib', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d164.s3.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d164.s3.e1'}, 'sentence_id': 'DDI-MedLine.d164.s3'}	vitro assay lapatinib induced HER2 expression cell surface HER2 positive breast cancer cell lines leading enhancement Herceptin mediated ADCC
Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. 	Herceptin	lapatinib	effect	{'e1': {'word': 'Herceptin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d164.s4.e0'}, 'e2': {'word': 'lapatinib', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d164.s4.e1'}, 'sentence_id': 'DDI-MedLine.d164.s4'}	Furthermore present case report second Herceptin treatment following lapatinib resulted marked shrinkage multiple metastatic tumors HER2 positive breast cancer
Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	Lapatinib	Herceptin	none	{'e1': {'word': 'Lapatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s5.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d164.s5.e1'}, 'sentence_id': 'DDI-MedLine.d164.s5'}	Lapatinib may potential convert Herceptin refractory Herceptin sensitive tumors HER2 positive breast cancer regulation cell surface expression HER2
Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	Lapatinib	Herceptin	none	{'e1': {'word': 'Lapatinib', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d164.s5.e0'}, 'e2': {'word': 'Herceptin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d164.s5.e2'}, 'sentence_id': 'DDI-MedLine.d164.s5'}	Lapatinib may potential convert Herceptin refractory Herceptin sensitive tumors HER2 positive breast cancer regulation cell surface expression HER2
Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	Herceptin	Herceptin	none	{'e1': {'word': 'Herceptin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d164.s5.e1'}, 'e2': {'word': 'Herceptin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d164.s5.e2'}, 'sentence_id': 'DDI-MedLine.d164.s5'}	Lapatinib may potential convert Herceptin refractory Herceptin sensitive tumors HER2 positive breast cancer regulation cell surface expression HER2
"In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
"	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d213.s0.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d213.s0.e1'}, 'sentence_id': 'DDI-MedLine.d213.s0'}	vivo CYP3A activity significantly lower cyclosporine treated compared tacrolimus treated renal allograft recipients
In vitro studies have identified cyclosporine and tacrolimus as CYP3A inhibitors. 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d213.s1.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d213.s1.e1'}, 'sentence_id': 'DDI-MedLine.d213.s1'}	vitro studies identified cyclosporine tacrolimus CYP3A inhibitors
Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). 	midazolam	cyclosporine	mechanism	{'e1': {'word': 'midazolam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d213.s3.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d213.s3.e1'}, 'sentence_id': 'DDI-MedLine.d213.s3'}	Systemic apparent oral midazolam clearance NUMBER % NUMBER NUMBER vs. NUMBER NUMBER ml / min P = NUMBER NUMBER % NUMBER NUMBER vs. NUMBER NUMBER ml / min P = NUMBER respectively lower cyclosporine treated patients n = NUMBER matched tacrolimus treated patients n = NUMBER
Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). 	midazolam	tacrolimus	none	{'e1': {'word': 'midazolam', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d213.s3.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d213.s3.e2'}, 'sentence_id': 'DDI-MedLine.d213.s3'}	Systemic apparent oral midazolam clearance NUMBER % NUMBER NUMBER vs. NUMBER NUMBER ml / min P = NUMBER NUMBER % NUMBER NUMBER vs. NUMBER NUMBER ml / min P = NUMBER respectively lower cyclosporine treated patients n = NUMBER matched tacrolimus treated patients n = NUMBER
Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(33, 33)], 'id': 'DDI-MedLine.d213.s3.e1'}, 'e2': {'word': 'tacrolimus', 'word_index': [(40, 40)], 'id': 'DDI-MedLine.d213.s3.e2'}, 'sentence_id': 'DDI-MedLine.d213.s3'}	Systemic apparent oral midazolam clearance NUMBER % NUMBER NUMBER vs. NUMBER NUMBER ml / min P = NUMBER NUMBER % NUMBER NUMBER vs. NUMBER NUMBER ml / min P = NUMBER respectively lower cyclosporine treated patients n = NUMBER matched tacrolimus treated patients n = NUMBER
The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). 	midazolam	tacrolimus	none	{'e1': {'word': 'midazolam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d213.s4.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d213.s4.e1'}, 'sentence_id': 'DDI-MedLine.d213.s4'}	latter displayed midazolam clearances similar NUMBER larger cohorts nonmatched tacrolimus treated patients n = NUMBER n = NUMBER receiving calcineurin inhibitor free regimen n = NUMBER
The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). 	midazolam	calcineurin inhibitor	none	{'e1': {'word': 'midazolam', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d213.s4.e0'}, 'e2': {'word': 'calcineurin inhibitor', 'word_index': [(19, 20)], 'id': 'DDI-MedLine.d213.s4.e2'}, 'sentence_id': 'DDI-MedLine.d213.s4'}	latter displayed midazolam clearances similar NUMBER larger cohorts nonmatched tacrolimus treated patients n = NUMBER n = NUMBER receiving calcineurin inhibitor free regimen n = NUMBER
The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). 	tacrolimus	calcineurin inhibitor	none	{'e1': {'word': 'tacrolimus', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d213.s4.e1'}, 'e2': {'word': 'calcineurin inhibitor', 'word_index': [(19, 20)], 'id': 'DDI-MedLine.d213.s4.e2'}, 'sentence_id': 'DDI-MedLine.d213.s4'}	latter displayed midazolam clearances similar NUMBER larger cohorts nonmatched tacrolimus treated patients n = NUMBER n = NUMBER receiving calcineurin inhibitor free regimen n = NUMBER
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. 	cyclosporine	tacrolimus	none	{'e1': {'word': 'cyclosporine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d213.s5.e0'}, 'e2': {'word': 'tacrolimus', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d213.s5.e1'}, 'sentence_id': 'DDI-MedLine.d213.s5'}	implies vivo hepatic first pass CYP3A activities significantly lower patients receiving cyclosporine receiving tacrolimus indicating doses generally used clinical practice cyclosporine stronger NUMBER respect CYP3A inhibition
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. 	cyclosporine	cyclosporine	none	{'e1': {'word': 'cyclosporine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d213.s5.e0'}, 'e2': {'word': 'cyclosporine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d213.s5.e2'}, 'sentence_id': 'DDI-MedLine.d213.s5'}	implies vivo hepatic first pass CYP3A activities significantly lower patients receiving cyclosporine receiving tacrolimus indicating doses generally used clinical practice cyclosporine stronger NUMBER respect CYP3A inhibition
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. 	tacrolimus	cyclosporine	none	{'e1': {'word': 'tacrolimus', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d213.s5.e1'}, 'e2': {'word': 'cyclosporine', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d213.s5.e2'}, 'sentence_id': 'DDI-MedLine.d213.s5'}	implies vivo hepatic first pass CYP3A activities significantly lower patients receiving cyclosporine receiving tacrolimus indicating doses generally used clinical practice cyclosporine stronger NUMBER respect CYP3A inhibition
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	ketoconazole	panobinostat	none	{'e1': {'word': 'ketoconazole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d185.s0.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d185.s0.e1'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	Effect ketoconazole mediated CYP3A4 inhibition clinical pharmacokinetics panobinostat LBH589 orally active histone deacetylase inhibitor
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	ketoconazole	LBH589	none	{'e1': {'word': 'ketoconazole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d185.s0.e0'}, 'e2': {'word': 'LBH589', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d185.s0.e2'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	Effect ketoconazole mediated CYP3A4 inhibition clinical pharmacokinetics panobinostat LBH589 orally active histone deacetylase inhibitor
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	ketoconazole	histone deacetylase inhibitor	none	{'e1': {'word': 'ketoconazole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d185.s0.e0'}, 'e2': {'word': 'histone deacetylase inhibitor', 'word_index': [(11, 13)], 'id': 'DDI-MedLine.d185.s0.e3'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	Effect ketoconazole mediated CYP3A4 inhibition clinical pharmacokinetics panobinostat LBH589 orally active histone deacetylase inhibitor
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	panobinostat	LBH589	none	{'e1': {'word': 'panobinostat', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d185.s0.e1'}, 'e2': {'word': 'LBH589', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d185.s0.e2'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	Effect ketoconazole mediated CYP3A4 inhibition clinical pharmacokinetics panobinostat LBH589 orally active histone deacetylase inhibitor
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	panobinostat	histone deacetylase inhibitor	none	{'e1': {'word': 'panobinostat', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d185.s0.e1'}, 'e2': {'word': 'histone deacetylase inhibitor', 'word_index': [(11, 13)], 'id': 'DDI-MedLine.d185.s0.e3'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	Effect ketoconazole mediated CYP3A4 inhibition clinical pharmacokinetics panobinostat LBH589 orally active histone deacetylase inhibitor
"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
"	LBH589	histone deacetylase inhibitor	none	{'e1': {'word': 'LBH589', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d185.s0.e2'}, 'e2': {'word': 'histone deacetylase inhibitor', 'word_index': [(11, 13)], 'id': 'DDI-MedLine.d185.s0.e3'}, 'sentence_id': 'DDI-MedLine.d185.s0'}	Effect ketoconazole mediated CYP3A4 inhibition clinical pharmacokinetics panobinostat LBH589 orally active histone deacetylase inhibitor
This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat.	ketoconazole	panobinostat	none	{'e1': {'word': 'ketoconazole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d185.s2.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d185.s2.e1'}, 'sentence_id': 'DDI-MedLine.d185.s2'}	study evaluated effect potent CYP3A inhibitor ketoconazole pharmacokinetics safety panobinostat
On day 8, a single panobinostat dose was co-administered with ketoconazole. 	panobinostat	ketoconazole	none	{'e1': {'word': 'panobinostat', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d185.s5.e0'}, 'e2': {'word': 'ketoconazole', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d185.s5.e1'}, 'sentence_id': 'DDI-MedLine.d185.s5'}	day NUMBER single panobinostat dose co-administered ketoconazole
In the presence of ketoconazole, there was 1.6- and 1.8-fold increase in C (max) and AUC of panobinostat, respectively. 	ketoconazole	panobinostat	mechanism	{'e1': {'word': 'ketoconazole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d185.s7.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d185.s7.e1'}, 'sentence_id': 'DDI-MedLine.d185.s7'}	presence ketoconazole NUMBER 1.8-fold increase C max AUC panobinostat respectively
Co-administration of panobinostat with CYP3A inhibitors is feasible as the observed increase in panobinostat PK parameters was not considered clinically relevant. 	panobinostat	panobinostat	none	{'e1': {'word': 'panobinostat', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d185.s12.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d185.s12.e1'}, 'sentence_id': 'DDI-MedLine.d185.s12'}	Co-administration panobinostat CYP3A inhibitors feasible observed increase panobinostat PK parameters considered clinically relevant
Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of panobinostat was not studied with CYP3A inhibitors, close monitoring of panobinostat-related adverse events is necessary.	panobinostat	panobinostat	none	{'e1': {'word': 'panobinostat', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d185.s13.e0'}, 'e2': {'word': 'panobinostat', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d185.s13.e1'}, 'sentence_id': 'DDI-MedLine.d185.s13'}	Considering variability exposure following enzyme inhibition fact chronic dosing panobinostat studied CYP3A inhibitors close monitoring panobinostat related adverse events necessary
"Prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.
"	ketamine	propofol	none	{'e1': {'word': 'ketamine', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d199.s0.e0'}, 'e2': {'word': 'propofol', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d199.s0.e1'}, 'sentence_id': 'DDI-MedLine.d199.s0'}	Prevention emergence agitation NUMBER children receiving low dose ketamine propofol total intravenous anesthesia
We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. 	ketamine	propofol	none	{'e1': {'word': 'ketamine', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d199.s2.e0'}, 'e2': {'word': 'propofol', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d199.s2.e1'}, 'sentence_id': 'DDI-MedLine.d199.s2'}	retrospectively reviewed records NUMBER pediatric oncology patients received low dose ketamine conjunction propofol total intravenous anesthesia TIVA repeatedly radiation therapy
EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. 	propofol	ketamine	none	{'e1': {'word': 'propofol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d199.s3.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d199.s3.e1'}, 'sentence_id': 'DDI-MedLine.d199.s3'}	EA signs observed NUMBER patients association propofol TIVA recur NUMBER subsequent anesthetics sessions low dose ketamine added propofol
EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. 	propofol	propofol	none	{'e1': {'word': 'propofol', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d199.s3.e0'}, 'e2': {'word': 'propofol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d199.s3.e2'}, 'sentence_id': 'DDI-MedLine.d199.s3'}	EA signs observed NUMBER patients association propofol TIVA recur NUMBER subsequent anesthetics sessions low dose ketamine added propofol
EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. 	ketamine	propofol	none	{'e1': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d199.s3.e1'}, 'e2': {'word': 'propofol', 'word_index': [(17, 17)], 'id': 'DDI-MedLine.d199.s3.e2'}, 'sentence_id': 'DDI-MedLine.d199.s3'}	EA signs observed NUMBER patients association propofol TIVA recur NUMBER subsequent anesthetics sessions low dose ketamine added propofol
Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.	ketamine	propofol	effect	{'e1': {'word': 'ketamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d199.s4.e0'}, 'e2': {'word': 'propofol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d199.s4.e1'}, 'sentence_id': 'DDI-MedLine.d199.s4'}	Based experience suggest low dose ketamine added propofol may associated prevention EA children history EA propofol TIVA
Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.	ketamine	propofol	none	{'e1': {'word': 'ketamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d199.s4.e0'}, 'e2': {'word': 'propofol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d199.s4.e2'}, 'sentence_id': 'DDI-MedLine.d199.s4'}	Based experience suggest low dose ketamine added propofol may associated prevention EA children history EA propofol TIVA
Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.	propofol	propofol	none	{'e1': {'word': 'propofol', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d199.s4.e1'}, 'e2': {'word': 'propofol', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d199.s4.e2'}, 'sentence_id': 'DDI-MedLine.d199.s4'}	Based experience suggest low dose ketamine added propofol may associated prevention EA children history EA propofol TIVA
Protective effect of acetyl-l-carnitine and  alpha lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes.	acetyl-l-carnitine	alpha lipoic acid	none	{'e1': {'word': 'acetyl-l-carnitine', 'word_index': [(2, 4)], 'id': 'DDI-MedLine.d159.s0.e0'}, 'e2': {'word': 'alpha lipoic acid', 'word_index': [(5, 7)], 'id': 'DDI-MedLine.d159.s0.e1'}, 'sentence_id': 'DDI-MedLine.d159.s0'}	Protective effect acetyl l carnitine alpha lipoic acid acute toxicity diepoxybutane human lymphocytes
(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.	acetyl-l-carnitine	alpha-lipoic acid	effect	{'e1': {'word': 'acetyl-l-carnitine', 'word_index': [(1, 3)], 'id': 'DDI-MedLine.d159.s6.e0'}, 'e2': {'word': 'alpha-lipoic acid', 'word_index': [(12, 14)], 'id': 'DDI-MedLine.d159.s6.e1'}, 'sentence_id': 'DDI-MedLine.d159.s6'}	ii acetyl l carnitine elicits significant protective effect DEB induced toxicity potentiated alpha lipoic acid
"Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens.
"	avian influenza vaccines	ginseng stem-and-leaf saponins	none	{'e1': {'word': 'avian influenza vaccines', 'word_index': [(7, 9)], 'id': 'DDI-MedLine.d154.s0.e0'}, 'e2': {'word': 'ginseng stem-and-leaf saponins', 'word_index': [(12, 15)], 'id': 'DDI-MedLine.d154.s0.e1'}, 'sentence_id': 'DDI-MedLine.d154.s0'}	Enhancement humoral immune responses inactivated Newcastle disease avian influenza vaccines oral administration ginseng stem leaf saponins chickens
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	ginseng stem-and-leaf saponins	GSLS	none	{'e1': {'word': 'ginseng stem-and-leaf saponins', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d154.s2.e0'}, 'e2': {'word': 'GSLS', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d154.s2.e1'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	objective study evaluate effect oral administration ginseng stem leaf saponins GSLS humoral immune responses chickens inactivated ND inactivated ND AI vaccines
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	ginseng stem-and-leaf saponins	inactivated ND vaccines	none	{'e1': {'word': 'ginseng stem-and-leaf saponins', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d154.s2.e0'}, 'e2': {'word': 'inactivated ND vaccines', 'word_index': [(15, 16), (20, 20)], 'id': 'DDI-MedLine.d154.s2.e2'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	objective study evaluate effect oral administration ginseng stem leaf saponins GSLS humoral immune responses chickens inactivated ND inactivated ND AI vaccines
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	ginseng stem-and-leaf saponins	inactivated AI vaccines	none	{'e1': {'word': 'ginseng stem-and-leaf saponins', 'word_index': [(6, 9)], 'id': 'DDI-MedLine.d154.s2.e0'}, 'e2': {'word': 'inactivated AI vaccines', 'word_index': [(15, 15), (18, 18), (19, 19)], 'id': 'DDI-MedLine.d154.s2.e3'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	objective study evaluate effect oral administration ginseng stem leaf saponins GSLS humoral immune responses chickens inactivated inactivated ND AI vaccines
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	GSLS	inactivated ND vaccines	none	{'e1': {'word': 'GSLS', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d154.s2.e1'}, 'e2': {'word': 'inactivated ND vaccines', 'word_index': [(15, 16), (20, 20)], 'id': 'DDI-MedLine.d154.s2.e2'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	objective study evaluate effect oral administration ginseng stem leaf saponins GSLS humoral immune responses chickens inactivated ND inactivated ND AI vaccines
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	GSLS	inactivated AI vaccines	none	{'e1': {'word': 'GSLS', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d154.s2.e1'}, 'e2': {'word': 'inactivated AI vaccines', 'word_index': [(15, 15), (18, 18), (19, 19)], 'id': 'DDI-MedLine.d154.s2.e3'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	objective study evaluate effect oral administration ginseng stem leaf saponins GSLS humoral immune responses chickens inactivated inactivated ND AI vaccines
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 	inactivated ND vaccines	inactivated AI vaccines	none	{'e1': {'word': 'inactivated ND vaccines', 'word_index': [(15, 16), (20, 20)], 'id': 'DDI-MedLine.d154.s2.e2'}, 'e2': {'word': 'inactivated AI vaccines', 'word_index': [(17, 17), (19, 19), (20, 20)], 'id': 'DDI-MedLine.d154.s2.e3'}, 'sentence_id': 'DDI-MedLine.d154.s2'}	objective study evaluate effect oral administration ginseng stem leaf saponins GSLS humoral immune responses chickens inactivated ND inactivated ND AI vaccines
In experiment 1, oral administration of GSLS at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with inactivated ND vaccine was evaluated. 	GSLS	inactivated ND vaccine	none	{'e1': {'word': 'GSLS', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d154.s3.e0'}, 'e2': {'word': 'inactivated ND vaccine', 'word_index': [(17, 19)], 'id': 'DDI-MedLine.d154.s3.e1'}, 'sentence_id': 'DDI-MedLine.d154.s3'}	experiment NUMBER oral administration GSLS dose NUMBER mg / kg BW NUMBER immune response chickens intramuscularly injected inactivated ND vaccine evaluated
In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed. 	GSLS	inactivated AI vaccines	effect	{'e1': {'word': 'GSLS', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d154.s5.e0'}, 'e2': {'word': 'inactivated AI vaccines', 'word_index': [(7, 9)], 'id': 'DDI-MedLine.d154.s5.e1'}, 'sentence_id': 'DDI-MedLine.d154.s5'}	experiment NUMBER regimen GSLS administered chickens inoculated inactivated AI vaccines enhanced serum antibody response AI vaccination also observed
Considering the safety of GSLS, because no adverse effect was found throughout the experiments, GSLS may be a promising oral adjuvant to improve immunization in poultry.	GSLS	GSLS	none	{'e1': {'word': 'GSLS', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d154.s6.e0'}, 'e2': {'word': 'GSLS', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d154.s6.e1'}, 'sentence_id': 'DDI-MedLine.d154.s6'}	Considering safety GSLS adverse effect found throughout experiments GSLS may promising oral adjuvant improve immunization poultry
"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
"	S-ketamine	itraconazole	none	{'e1': {'word': 'S-ketamine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d216.s0.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d216.s0.e1'}, 'sentence_id': 'DDI-MedLine.d216.s0'}	Exposure oral ketamine unaffected itraconazole greatly increased ticlopidine
"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
"	S-ketamine	ticlopidine	effect	{'e1': {'word': 'S-ketamine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d216.s0.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d216.s0.e2'}, 'sentence_id': 'DDI-MedLine.d216.s0'}	Exposure oral ketamine unaffected itraconazole greatly increased ticlopidine
"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
"	itraconazole	ticlopidine	none	{'e1': {'word': 'itraconazole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d216.s0.e1'}, 'e2': {'word': 'ticlopidine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d216.s0.e2'}, 'sentence_id': 'DDI-MedLine.d216.s0'}	Exposure oral ketamine unaffected itraconazole greatly increased ticlopidine
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. 	S-ketamine	ticlopidine	none	{'e1': {'word': 'S-ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s1.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d216.s1.e1'}, 'sentence_id': 'DDI-MedLine.d216.s1'}	study examined drug drug interactions oral ketamine cytochrome P450 CYP 2B6 inhibitor ticlopidine CYP3A inhibitor itraconazole
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. 	S-ketamine	itraconazole	none	{'e1': {'word': 'S-ketamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d216.s1.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d216.s1.e2'}, 'sentence_id': 'DDI-MedLine.d216.s1'}	study examined drug drug interactions oral ketamine cytochrome P450 CYP 2B6 inhibitor ticlopidine CYP3A inhibitor itraconazole
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. 	ticlopidine	itraconazole	none	{'e1': {'word': 'ticlopidine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d216.s1.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d216.s1.e2'}, 'sentence_id': 'DDI-MedLine.d216.s1'}	study examined drug drug interactions oral ketamine cytochrome P450 CYP 2B6 inhibitor ticlopidine CYP3A inhibitor itraconazole
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. 	S-ketamine	ticlopidine	none	{'e1': {'word': 'S-ketamine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d216.s2.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d216.s2.e1'}, 'sentence_id': 'DDI-MedLine.d216.s2'}	randomized blinded crossover study NUMBER healthy volunteers ingested NUMBER mg / kg ketamine pretreatments oral ticlopidine NUMBER mg twice daily itraconazole NUMBER mg daily placebo NUMBER day treatment periods intervals NUMBER weeks
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. 	S-ketamine	itraconazole	none	{'e1': {'word': 'S-ketamine', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d216.s2.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d216.s2.e2'}, 'sentence_id': 'DDI-MedLine.d216.s2'}	randomized blinded crossover study NUMBER healthy volunteers ingested NUMBER mg / kg ketamine pretreatments oral ticlopidine NUMBER mg twice daily itraconazole NUMBER mg daily placebo NUMBER day treatment periods intervals NUMBER weeks
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. 	ticlopidine	itraconazole	none	{'e1': {'word': 'ticlopidine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d216.s2.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d216.s2.e2'}, 'sentence_id': 'DDI-MedLine.d216.s2'}	randomized blinded crossover study NUMBER healthy volunteers ingested NUMBER mg / kg ketamine pretreatments oral ticlopidine NUMBER mg twice daily itraconazole NUMBER mg daily placebo NUMBER day treatment periods intervals NUMBER weeks
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	Ticlopidine	ketamine	mechanism	{'e1': {'word': 'Ticlopidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d216.s3.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d216.s3.e1'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	Ticlopidine treatment increased mean area plasma concentration time curve extrapolated infinity AUC NUMBER - oral ketamine 2.4-fold whereas itraconazole treatment increase exposure ketamine
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	Ticlopidine	itraconazole	none	{'e1': {'word': 'Ticlopidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d216.s3.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d216.s3.e2'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	Ticlopidine treatment increased mean area plasma concentration time curve extrapolated infinity AUC NUMBER - oral ketamine 2.4-fold whereas itraconazole treatment increase exposure ketamine
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	Ticlopidine	S-ketamine	none	{'e1': {'word': 'Ticlopidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d216.s3.e0'}, 'e2': {'word': 'S-ketamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d216.s3.e3'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	Ticlopidine treatment increased mean area plasma concentration time curve extrapolated infinity AUC NUMBER - oral ketamine 2.4-fold whereas itraconazole treatment increase exposure ketamine
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	ketamine	itraconazole	none	{'e1': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d216.s3.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d216.s3.e2'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	Ticlopidine treatment increased mean area plasma concentration time curve extrapolated infinity AUC NUMBER - oral ketamine 2.4-fold whereas itraconazole treatment increase exposure ketamine
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	ketamine	S-ketamine	none	{'e1': {'word': 'ketamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d216.s3.e1'}, 'e2': {'word': 'S-ketamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d216.s3.e3'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	Ticlopidine treatment increased mean area plasma concentration time curve extrapolated infinity AUC NUMBER - oral ketamine 2.4-fold whereas itraconazole treatment increase exposure ketamine
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 	itraconazole	S-ketamine	none	{'e1': {'word': 'itraconazole', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d216.s3.e2'}, 'e2': {'word': 'S-ketamine', 'word_index': [(22, 22)], 'id': 'DDI-MedLine.d216.s3.e3'}, 'sentence_id': 'DDI-MedLine.d216.s3'}	Ticlopidine treatment increased mean area plasma concentration time curve extrapolated infinity AUC NUMBER - oral ketamine 2.4-fold whereas itraconazole treatment increase exposure ketamine
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	norketamine	ketamine	none	{'e1': {'word': 'norketamine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d216.s4.e0'}, 'e2': {'word': 'ketamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d216.s4.e1'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	ratio norketamine AUC NUMBER - ketamine AUC NUMBER - significantly decreased ticlopidine P &lt NUMBER itraconazole phases P = NUMBER compared placebo
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	norketamine	ticlopidine	none	{'e1': {'word': 'norketamine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d216.s4.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d216.s4.e2'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	ratio norketamine AUC NUMBER - ketamine AUC NUMBER - significantly decreased ticlopidine P &lt NUMBER itraconazole phases P = NUMBER compared placebo
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	norketamine	itraconazole	none	{'e1': {'word': 'norketamine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d216.s4.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d216.s4.e3'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	ratio norketamine AUC NUMBER - ketamine AUC NUMBER - significantly decreased ticlopidine P &lt NUMBER itraconazole phases P = NUMBER compared placebo
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	ketamine	ticlopidine	none	{'e1': {'word': 'ketamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d216.s4.e1'}, 'e2': {'word': 'ticlopidine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d216.s4.e2'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	ratio norketamine AUC NUMBER - ketamine AUC NUMBER - significantly decreased ticlopidine P &lt NUMBER itraconazole phases P = NUMBER compared placebo
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	ketamine	itraconazole	none	{'e1': {'word': 'ketamine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d216.s4.e1'}, 'e2': {'word': 'itraconazole', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d216.s4.e3'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	ratio norketamine AUC NUMBER - ketamine AUC NUMBER - significantly decreased ticlopidine P &lt NUMBER itraconazole phases P = NUMBER compared placebo
The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 	ticlopidine	itraconazole	none	{'e1': {'word': 'ticlopidine', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d216.s4.e2'}, 'e2': {'word': 'itraconazole', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d216.s4.e3'}, 'sentence_id': 'DDI-MedLine.d216.s4'}	ratio norketamine AUC NUMBER - ketamine AUC NUMBER - significantly decreased ticlopidine P &lt NUMBER itraconazole phases P = NUMBER compared placebo
In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). 	ticlopidine	itraconazole	none	{'e1': {'word': 'ticlopidine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d216.s5.e0'}, 'e2': {'word': 'itraconazole', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d216.s5.e1'}, 'sentence_id': 'DDI-MedLine.d216.s5'}	ticlopidine itraconazole phases areas effect time curves self reported drowsiness performance significantly higher placebo phase P < NUMBER
The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.	S-ketamine	ticlopidine	advise	{'e1': {'word': 'S-ketamine', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d216.s6.e0'}, 'e2': {'word': 'ticlopidine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d216.s6.e1'}, 'sentence_id': 'DDI-MedLine.d216.s6'}	findings suggest dosage ketamine reduced patients receiving ticlopidine
"Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa.
"	piperacillin	methylglyoxal	none	{'e1': {'word': 'piperacillin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d204.s0.e0'}, 'e2': {'word': 'methylglyoxal', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d204.s0.e1'}, 'sentence_id': 'DDI-MedLine.d204.s0'}	Distinct synergistic action piperacillin methylglyoxal Pseudomonas aeruginosa
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	piperacillin	carbenicillin	none	{'e1': {'word': 'piperacillin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d204.s7.e0'}, 'e2': {'word': 'carbenicillin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d204.s7.e1'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	Results revealed strains resistant many drugs high levels piperacillin carbenicillin amikacin ciprofloxacin showed resistances comparatively lower levels
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	piperacillin	amikacin	none	{'e1': {'word': 'piperacillin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d204.s7.e0'}, 'e2': {'word': 'amikacin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d204.s7.e2'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	Results revealed strains resistant many drugs high levels piperacillin carbenicillin amikacin ciprofloxacin showed resistances comparatively lower levels
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	piperacillin	ciprofloxacin	none	{'e1': {'word': 'piperacillin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d204.s7.e0'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d204.s7.e3'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	Results revealed strains resistant many drugs high levels piperacillin carbenicillin amikacin ciprofloxacin showed resistances comparatively lower levels
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	carbenicillin	amikacin	none	{'e1': {'word': 'carbenicillin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d204.s7.e1'}, 'e2': {'word': 'amikacin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d204.s7.e2'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	Results revealed strains resistant many drugs high levels piperacillin carbenicillin amikacin ciprofloxacin showed resistances comparatively lower levels
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	carbenicillin	ciprofloxacin	none	{'e1': {'word': 'carbenicillin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d204.s7.e1'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d204.s7.e3'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	Results revealed strains resistant many drugs high levels piperacillin carbenicillin amikacin ciprofloxacin showed resistances comparatively lower levels
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. 	amikacin	ciprofloxacin	none	{'e1': {'word': 'amikacin', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d204.s7.e2'}, 'e2': {'word': 'ciprofloxacin', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d204.s7.e3'}, 'sentence_id': 'DDI-MedLine.d204.s7'}	Results revealed strains resistant many drugs high levels piperacillin carbenicillin amikacin ciprofloxacin showed resistances comparatively lower levels
Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects. 	methylglyoxal	piperacillin	effect	{'e1': {'word': 'methylglyoxal', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d204.s9.e0'}, 'e2': {'word': 'piperacillin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d204.s9.e1'}, 'sentence_id': 'DDI-MedLine.d204.s9'}	Distinct statistically significant synergism observed methylglyoxal piperacillin disc diffusion tests compared individual effects
Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.	methylglyoxal	carbenicillin	effect	{'e1': {'word': 'methylglyoxal', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d204.s11.e0'}, 'e2': {'word': 'carbenicillin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d204.s11.e1'}, 'sentence_id': 'DDI-MedLine.d204.s11'}	Synergism also noted methylglyoxal combined carbenicillin amikacin
Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.	methylglyoxal	amikacin	effect	{'e1': {'word': 'methylglyoxal', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d204.s11.e0'}, 'e2': {'word': 'amikacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d204.s11.e2'}, 'sentence_id': 'DDI-MedLine.d204.s11'}	Synergism also noted methylglyoxal combined carbenicillin amikacin
Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.	carbenicillin	amikacin	none	{'e1': {'word': 'carbenicillin', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d204.s11.e1'}, 'e2': {'word': 'amikacin', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d204.s11.e2'}, 'sentence_id': 'DDI-MedLine.d204.s11'}	Synergism also noted methylglyoxal combined carbenicillin amikacin
The 3-Deazaneplanocin A (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. 	3-Deazaneplanocin A	DZNep	none	{'e1': {'word': '3-Deazaneplanocin A', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d180.s1.e0'}, 'e2': {'word': 'DZNep', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d180.s1.e1'}, 'sentence_id': 'DDI-MedLine.d180.s1'}	NUMBER Deazaneplanocin DZNep NUMBER adenosylhomocysteine AdoHcy hydrolase inhibitors shown antitumor activities broad range solid tumors acute myeloid leukemia
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	DZNep	none	{'e1': {'word': 'DZNep', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d180.s10.e0'}, 'e2': {'word': 'DZNep', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d180.s10.e1'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	also found Bcl NUMBER overexpressed DZNep insensitive cells cotreatment DZNep ABT NUMBER Bcl NUMBER family inhibitor synergistically inhibited growth induced apoptosis DZNep insensitive MM cells
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	ABT-737	none	{'e1': {'word': 'DZNep', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d180.s10.e0'}, 'e2': {'word': 'ABT-737', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d180.s10.e2'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	also found Bcl NUMBER overexpressed DZNep insensitive cells cotreatment DZNep ABT NUMBER Bcl NUMBER family inhibitor synergistically inhibited growth induced apoptosis DZNep insensitive MM cells
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	DZNep	none	{'e1': {'word': 'DZNep', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d180.s10.e0'}, 'e2': {'word': 'DZNep', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d180.s10.e3'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	also found Bcl NUMBER overexpressed DZNep insensitive cells cotreatment DZNep ABT NUMBER Bcl NUMBER family inhibitor synergistically inhibited growth induced apoptosis DZNep insensitive MM cells
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	ABT-737	effect	{'e1': {'word': 'DZNep', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d180.s10.e1'}, 'e2': {'word': 'ABT-737', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d180.s10.e2'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	also found Bcl NUMBER overexpressed DZNep insensitive cells cotreatment DZNep ABT NUMBER Bcl NUMBER family inhibitor synergistically inhibited growth induced apoptosis DZNep insensitive MM cells
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	DZNep	DZNep	none	{'e1': {'word': 'DZNep', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d180.s10.e1'}, 'e2': {'word': 'DZNep', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d180.s10.e3'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	also found Bcl NUMBER overexpressed DZNep insensitive cells cotreatment DZNep ABT NUMBER Bcl NUMBER family inhibitor synergistically inhibited growth induced apoptosis DZNep insensitive MM cells
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 	ABT-737	DZNep	none	{'e1': {'word': 'ABT-737', 'word_index': [(10, 11)], 'id': 'DDI-MedLine.d180.s10.e2'}, 'e2': {'word': 'DZNep', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d180.s10.e3'}, 'sentence_id': 'DDI-MedLine.d180.s10'}	also found Bcl NUMBER overexpressed DZNep insensitive cells cotreatment DZNep ABT NUMBER Bcl NUMBER family inhibitor synergistically inhibited growth induced apoptosis DZNep insensitive MM cells
In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. 	DZNep	ABT-737	none	{'e1': {'word': 'DZNep', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d180.s12.e0'}, 'e2': {'word': 'ABT-737', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d180.s12.e1'}, 'sentence_id': 'DDI-MedLine.d180.s12'}	addition DZNep insensitivity might associated overexpression Bcl NUMBER combination ABT NUMBER DZNep could synergistically induced apoptosis
In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. 	DZNep	DZNep	none	{'e1': {'word': 'DZNep', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d180.s12.e0'}, 'e2': {'word': 'DZNep', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d180.s12.e2'}, 'sentence_id': 'DDI-MedLine.d180.s12'}	addition DZNep insensitivity might associated overexpression Bcl NUMBER combination ABT NUMBER DZNep could synergistically induced apoptosis
In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. 	ABT-737	DZNep	effect	{'e1': {'word': 'ABT-737', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d180.s12.e1'}, 'e2': {'word': 'DZNep', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d180.s12.e2'}, 'sentence_id': 'DDI-MedLine.d180.s12'}	addition DZNep insensitivity might associated overexpression Bcl NUMBER combination ABT NUMBER DZNep could synergistically induced apoptosis
"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
"	minocycline	fosfomycin	none	{'e1': {'word': 'minocycline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d163.s0.e0'}, 'e2': {'word': 'fosfomycin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d163.s0.e1'}, 'sentence_id': 'DDI-MedLine.d163.s0'}	vitro activity minocycline combined fosfomycin clinical isolates methicillin resistant Staphylococcus aureus
"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
"	minocycline	methicillin	none	{'e1': {'word': 'minocycline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d163.s0.e0'}, 'e2': {'word': 'methicillin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d163.s0.e2'}, 'sentence_id': 'DDI-MedLine.d163.s0'}	vitro activity minocycline combined fosfomycin clinical isolates methicillin resistant Staphylococcus aureus
"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
"	fosfomycin	methicillin	none	{'e1': {'word': 'fosfomycin', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d163.s0.e1'}, 'e2': {'word': 'methicillin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d163.s0.e2'}, 'sentence_id': 'DDI-MedLine.d163.s0'}	vitro activity minocycline combined fosfomycin clinical isolates methicillin resistant Staphylococcus aureus
This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). 	minocycline	fosfomycin	none	{'e1': {'word': 'minocycline', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d163.s1.e0'}, 'e2': {'word': 'fosfomycin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d163.s1.e1'}, 'sentence_id': 'DDI-MedLine.d163.s1'}	study aimed evaluate vitro activity minocycline combined fosfomycin isolates methicillin resistant Staphylococcus aureus MRSA
This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). 	minocycline	methicillin	none	{'e1': {'word': 'minocycline', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d163.s1.e0'}, 'e2': {'word': 'methicillin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d163.s1.e2'}, 'sentence_id': 'DDI-MedLine.d163.s1'}	study aimed evaluate vitro activity minocycline combined fosfomycin isolates methicillin resistant Staphylococcus aureus MRSA
This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). 	fosfomycin	methicillin	none	{'e1': {'word': 'fosfomycin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d163.s1.e1'}, 'e2': {'word': 'methicillin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d163.s1.e2'}, 'sentence_id': 'DDI-MedLine.d163.s1'}	study aimed evaluate vitro activity minocycline combined fosfomycin isolates methicillin resistant Staphylococcus aureus MRSA
The susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria. 	minocycline	fosfomycin	none	{'e1': {'word': 'minocycline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d163.s4.e0'}, 'e2': {'word': 'fosfomycin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d163.s4.e1'}, 'sentence_id': 'DDI-MedLine.d163.s4'}	susceptibility results minocycline fosfomycin interpreted according relevant criteria
The combination of minocycline and fosfomycin can be synergistic against MRSA. 	minocycline	fosfomycin	effect	{'e1': {'word': 'minocycline', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d163.s7.e0'}, 'e2': {'word': 'fosfomycin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d163.s7.e1'}, 'sentence_id': 'DDI-MedLine.d163.s7'}	combination minocycline fosfomycin synergistic MRSA
In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(11, 20)], 'id': 'DDI-MedLine.d161.s3.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(33, 41)], 'id': 'DDI-MedLine.d161.s3.e1'}, 'sentence_id': 'DDI-MedLine.d161.s3'}	present study tested whether highly specific metabotropic glutamate receptor NUMBER antagonist NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine reduces dopaminergic noradrenergic neuronal loss monkeys rendered parkinsonian chronic treatment low doses NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(2, 10)], 'id': 'DDI-MedLine.d161.s4.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(23, 32)], 'id': 'DDI-MedLine.d161.s4.e1'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine injections NUMBER - NUMBER mg / kg body weight combination daily administration NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine vehicle performed development parkinsonian motor symptoms either NUMBER experimental groups NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine versus NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(2, 10)], 'id': 'DDI-MedLine.d161.s4.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(43, 51)], 'id': 'DDI-MedLine.d161.s4.e2'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine injections NUMBER - NUMBER mg / kg body weight combination daily administration NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine vehicle performed development parkinsonian motor symptoms either NUMBER experimental groups NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine versus NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(2, 10)], 'id': 'DDI-MedLine.d161.s4.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(52, 61)], 'id': 'DDI-MedLine.d161.s4.e3'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine injections NUMBER - NUMBER mg / kg body weight combination daily administration NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine vehicle performed development parkinsonian motor symptoms either NUMBER experimental groups NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine versus NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(2, 10)], 'id': 'DDI-MedLine.d161.s4.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(63, 71)], 'id': 'DDI-MedLine.d161.s4.e4'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine injections NUMBER - NUMBER mg / kg body weight combination daily administration NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine vehicle performed development parkinsonian motor symptoms either NUMBER experimental groups NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine versus NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(23, 32)], 'id': 'DDI-MedLine.d161.s4.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(43, 51)], 'id': 'DDI-MedLine.d161.s4.e2'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine injections NUMBER - NUMBER mg / kg body weight combination daily administration NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine vehicle performed development parkinsonian motor symptoms either NUMBER experimental groups NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine versus NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(23, 32)], 'id': 'DDI-MedLine.d161.s4.e1'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(52, 61)], 'id': 'DDI-MedLine.d161.s4.e3'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine injections NUMBER - NUMBER mg / kg body weight combination daily administration NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine vehicle performed development parkinsonian motor symptoms either NUMBER experimental groups NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine versus NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(23, 32)], 'id': 'DDI-MedLine.d161.s4.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(63, 71)], 'id': 'DDI-MedLine.d161.s4.e4'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine injections NUMBER - NUMBER mg / kg body weight combination daily administration NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine vehicle performed development parkinsonian motor symptoms either NUMBER experimental groups NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine versus NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(43, 51)], 'id': 'DDI-MedLine.d161.s4.e2'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(52, 61)], 'id': 'DDI-MedLine.d161.s4.e3'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine injections NUMBER - NUMBER mg / kg body weight combination daily administration NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine vehicle performed development parkinsonian motor symptoms either NUMBER experimental groups NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine versus NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(43, 51)], 'id': 'DDI-MedLine.d161.s4.e2'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(63, 71)], 'id': 'DDI-MedLine.d161.s4.e4'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine injections NUMBER - NUMBER mg / kg body weight combination daily administration NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine vehicle performed development parkinsonian motor symptoms either NUMBER experimental groups NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine versus NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(52, 61)], 'id': 'DDI-MedLine.d161.s4.e3'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(63, 71)], 'id': 'DDI-MedLine.d161.s4.e4'}, 'sentence_id': 'DDI-MedLine.d161.s4'}	Weekly intramuscular NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine injections NUMBER - NUMBER mg / kg body weight combination daily administration NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine vehicle performed development parkinsonian motor symptoms either NUMBER experimental groups NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine versus NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(2, 10)], 'id': 'DDI-MedLine.d161.s5.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(12, 20)], 'id': 'DDI-MedLine.d161.s5.e1'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	NUMBER weeks NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine treatment NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle treated animals displayed parkinsonian symptoms whereas none NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treated monkeys significantly affected
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(2, 10)], 'id': 'DDI-MedLine.d161.s5.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(29, 37)], 'id': 'DDI-MedLine.d161.s5.e2'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	NUMBER weeks NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine treatment NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle treated animals displayed parkinsonian symptoms whereas none NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treated monkeys significantly affected
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(2, 10)], 'id': 'DDI-MedLine.d161.s5.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(38, 47)], 'id': 'DDI-MedLine.d161.s5.e3'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	NUMBER weeks NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine treatment NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle treated animals displayed parkinsonian symptoms whereas none NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treated monkeys significantly affected
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(12, 20)], 'id': 'DDI-MedLine.d161.s5.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(29, 37)], 'id': 'DDI-MedLine.d161.s5.e2'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	NUMBER weeks NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine treatment NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle treated animals displayed parkinsonian symptoms whereas none NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treated monkeys significantly affected
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(12, 20)], 'id': 'DDI-MedLine.d161.s5.e1'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(38, 47)], 'id': 'DDI-MedLine.d161.s5.e3'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	NUMBER weeks NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine treatment NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle treated animals displayed parkinsonian symptoms whereas none NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treated monkeys significantly affected
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	effect	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(29, 37)], 'id': 'DDI-MedLine.d161.s5.e2'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(38, 47)], 'id': 'DDI-MedLine.d161.s5.e3'}, 'sentence_id': 'DDI-MedLine.d161.s5'}	NUMBER weeks NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine treatment NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle treated animals displayed parkinsonian symptoms whereas none NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treated monkeys significantly affected
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	effect	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(28, 36)], 'id': 'DDI-MedLine.d161.s6.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(37, 46)], 'id': 'DDI-MedLine.d161.s6.e1'}, 'sentence_id': 'DDI-MedLine.d161.s6'}	behavioural observations consistent vivo positron emission tomography dopamine transporter imaging data post-mortem stereological counts midbrain dopaminergic neurons well striatal intensity measurements dopamine transporter tyrosine hydroxylase immunoreactivity significantly higher NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treated animals NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle treated monkeys
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(28, 36)], 'id': 'DDI-MedLine.d161.s6.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(49, 57)], 'id': 'DDI-MedLine.d161.s6.e2'}, 'sentence_id': 'DDI-MedLine.d161.s6'}	behavioural observations consistent vivo positron emission tomography dopamine transporter imaging data post-mortem stereological counts midbrain dopaminergic neurons well striatal intensity measurements dopamine transporter tyrosine hydroxylase immunoreactivity significantly higher NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treated animals NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle treated monkeys
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(37, 46)], 'id': 'DDI-MedLine.d161.s6.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(49, 57)], 'id': 'DDI-MedLine.d161.s6.e2'}, 'sentence_id': 'DDI-MedLine.d161.s6'}	behavioural observations consistent vivo positron emission tomography dopamine transporter imaging data post-mortem stereological counts midbrain dopaminergic neurons well striatal intensity measurements dopamine transporter tyrosine hydroxylase immunoreactivity significantly higher NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treated animals NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle treated monkeys
The 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups. 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	effect	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(0, 9)], 'id': 'DDI-MedLine.d161.s7.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(14, 22)], 'id': 'DDI-MedLine.d161.s7.e1'}, 'sentence_id': 'DDI-MedLine.d161.s7'}	NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treatment also significant effect NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine induced loss norepinephrine neurons locus coeruleus adjoining A5 A7 noradrenaline cell groups
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(0, 8)], 'id': 'DDI-MedLine.d161.s8.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(38, 46)], 'id': 'DDI-MedLine.d161.s8.e1'}, 'sentence_id': 'DDI-MedLine.d161.s8'}	NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle treated animals almost NUMBER % loss tyrosine hydroxylase positive norepinephrine neurons found locus coeruleus A5 A7 noradrenaline cell groups whereas extent neuronal loss lower NUMBER % control values NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treated monkeys
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(0, 8)], 'id': 'DDI-MedLine.d161.s8.e0'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(47, 56)], 'id': 'DDI-MedLine.d161.s8.e2'}, 'sentence_id': 'DDI-MedLine.d161.s8'}	NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle treated animals almost NUMBER % loss tyrosine hydroxylase positive norepinephrine neurons found locus coeruleus A5 A7 noradrenaline cell groups whereas extent neuronal loss lower NUMBER % control values NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treated monkeys
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. 	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	effect	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(38, 46)], 'id': 'DDI-MedLine.d161.s8.e1'}, 'e2': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(47, 56)], 'id': 'DDI-MedLine.d161.s8.e2'}, 'sentence_id': 'DDI-MedLine.d161.s8'}	NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine vehicle treated animals almost NUMBER % loss tyrosine hydroxylase positive norepinephrine neurons found locus coeruleus A5 A7 noradrenaline cell groups whereas extent neuronal loss lower NUMBER % control values NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine treated monkeys
Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. 	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	effect	{'e1': {'word': '3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine', 'word_index': [(9, 18)], 'id': 'DDI-MedLine.d161.s9.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine', 'word_index': [(21, 29)], 'id': 'DDI-MedLine.d161.s9.e1'}, 'sentence_id': 'DDI-MedLine.d161.s9'}	data demonstrate chronic treatment metabotropic glutamate receptor NUMBER antagonist NUMBER NUMBER methyl NUMBER NUMBER thiazol NUMBER yl ethynyl pyridine significantly reduces NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine toxicity towards dopaminergic noradrenergic cell groups non-human primates
To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of adeno-associated virus-2 (AAV2).	adeno-associated virus-2	AAV2	none	{'e1': {'word': 'adeno-associated virus-2', 'word_index': [(13, 15)], 'id': 'DDI-MedLine.d190.s1.e0'}, 'e2': {'word': 'AAV2', 'word_index': [(16, 16)], 'id': 'DDI-MedLine.d190.s1.e1'}, 'sentence_id': 'DDI-MedLine.d190.s1'}	determine whether co-injection extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery adeno-associated virus NUMBER AAV2
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	AAV2	collagenase	none	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s2.e0'}, 'e2': {'word': 'collagenase', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d190.s2.e1'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	AAV2 containing cDNA encoding enhanced green fluorescent protein GFP control chicken actin promoter delivered intravitreal injection adult mice conjunction enzymes including collagenase hyaluronan lyase heparinase NUMBER chondroitin ABC lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	AAV2	hyaluronan lyase	none	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s2.e0'}, 'e2': {'word': 'hyaluronan lyase', 'word_index': [(22, 23)], 'id': 'DDI-MedLine.d190.s2.e2'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	AAV2 containing cDNA encoding enhanced green fluorescent protein GFP control chicken actin promoter delivered intravitreal injection adult mice conjunction enzymes including collagenase hyaluronan lyase heparinase NUMBER chondroitin ABC lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	AAV2	heparinase III	none	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s2.e0'}, 'e2': {'word': 'heparinase III', 'word_index': [(24, 25)], 'id': 'DDI-MedLine.d190.s2.e3'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	AAV2 containing cDNA encoding enhanced green fluorescent protein GFP control chicken actin promoter delivered intravitreal injection adult mice conjunction enzymes including collagenase hyaluronan lyase heparinase NUMBER chondroitin ABC lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	AAV2	chondroitin ABC lyase	none	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s2.e0'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(26, 28)], 'id': 'DDI-MedLine.d190.s2.e4'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	AAV2 containing cDNA encoding enhanced green fluorescent protein GFP control chicken actin promoter delivered intravitreal injection adult mice conjunction enzymes including collagenase hyaluronan lyase heparinase NUMBER chondroitin ABC lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	collagenase	hyaluronan lyase	none	{'e1': {'word': 'collagenase', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d190.s2.e1'}, 'e2': {'word': 'hyaluronan lyase', 'word_index': [(22, 23)], 'id': 'DDI-MedLine.d190.s2.e2'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	AAV2 containing cDNA encoding enhanced green fluorescent protein GFP control chicken actin promoter delivered intravitreal injection adult mice conjunction enzymes including collagenase hyaluronan lyase heparinase NUMBER chondroitin ABC lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	collagenase	heparinase III	none	{'e1': {'word': 'collagenase', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d190.s2.e1'}, 'e2': {'word': 'heparinase III', 'word_index': [(24, 25)], 'id': 'DDI-MedLine.d190.s2.e3'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	AAV2 containing cDNA encoding enhanced green fluorescent protein GFP control chicken actin promoter delivered intravitreal injection adult mice conjunction enzymes including collagenase hyaluronan lyase heparinase NUMBER chondroitin ABC lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	collagenase	chondroitin ABC lyase	none	{'e1': {'word': 'collagenase', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d190.s2.e1'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(26, 28)], 'id': 'DDI-MedLine.d190.s2.e4'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	AAV2 containing cDNA encoding enhanced green fluorescent protein GFP control chicken actin promoter delivered intravitreal injection adult mice conjunction enzymes including collagenase hyaluronan lyase heparinase NUMBER chondroitin ABC lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	hyaluronan lyase	heparinase III	none	{'e1': {'word': 'hyaluronan lyase', 'word_index': [(22, 23)], 'id': 'DDI-MedLine.d190.s2.e2'}, 'e2': {'word': 'heparinase III', 'word_index': [(24, 25)], 'id': 'DDI-MedLine.d190.s2.e3'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	AAV2 containing cDNA encoding enhanced green fluorescent protein GFP control chicken actin promoter delivered intravitreal injection adult mice conjunction enzymes including collagenase hyaluronan lyase heparinase NUMBER chondroitin ABC lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	hyaluronan lyase	chondroitin ABC lyase	none	{'e1': {'word': 'hyaluronan lyase', 'word_index': [(22, 23)], 'id': 'DDI-MedLine.d190.s2.e2'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(26, 28)], 'id': 'DDI-MedLine.d190.s2.e4'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	AAV2 containing cDNA encoding enhanced green fluorescent protein GFP control chicken actin promoter delivered intravitreal injection adult mice conjunction enzymes including collagenase hyaluronan lyase heparinase NUMBER chondroitin ABC lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. 	heparinase III	chondroitin ABC lyase	none	{'e1': {'word': 'heparinase III', 'word_index': [(24, 25)], 'id': 'DDI-MedLine.d190.s2.e3'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(26, 28)], 'id': 'DDI-MedLine.d190.s2.e4'}, 'sentence_id': 'DDI-MedLine.d190.s2'}	AAV2 containing cDNA encoding enhanced green fluorescent protein GFP control chicken actin promoter delivered intravitreal injection adult mice conjunction enzymes including collagenase hyaluronan lyase heparinase NUMBER chondroitin ABC lyase
The addition of heparinase III or chondroitin ABC lyase greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. 	heparinase III	chondroitin ABC lyase	none	{'e1': {'word': 'heparinase III', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d190.s5.e0'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d190.s5.e1'}, 'sentence_id': 'DDI-MedLine.d190.s5'}	addition heparinase NUMBER chondroitin ABC lyase greatly enhanced transduction retinal ganglion cell layer increased depth transduction outer retina
Hyaluronan lyase had a limited effect and collagenase was ineffective. 	Hyaluronan lyase	collagenase	none	{'e1': {'word': 'Hyaluronan lyase', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d190.s6.e0'}, 'e2': {'word': 'collagenase', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d190.s6.e1'}, 'sentence_id': 'DDI-MedLine.d190.s6'}	Hyaluronan lyase limited effect collagenase ineffective
Electroretinograms survived with higher concentrations of heparinase III and chondroitin ABC lyase than were required for optimal retinal transduction. 	heparinase III	chondroitin ABC lyase	none	{'e1': {'word': 'heparinase III', 'word_index': [(4, 5)], 'id': 'DDI-MedLine.d190.s7.e0'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(6, 8)], 'id': 'DDI-MedLine.d190.s7.e1'}, 'sentence_id': 'DDI-MedLine.d190.s7'}	Electroretinograms survived higher concentrations heparinase NUMBER chondroitin ABC lyase required optimal retinal transduction
AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. 	AAV2	heparinase III	effect	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s8.e0'}, 'e2': {'word': 'heparinase III', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d190.s8.e1'}, 'sentence_id': 'DDI-MedLine.d190.s8'}	AAV2 mediated retinal transduction improved co-injection heparinase NUMBER chondroitin ABC lyase
AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. 	AAV2	chondroitin ABC lyase	effect	{'e1': {'word': 'AAV2', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d190.s8.e0'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(8, 10)], 'id': 'DDI-MedLine.d190.s8.e2'}, 'sentence_id': 'DDI-MedLine.d190.s8'}	AAV2 mediated retinal transduction improved co-injection heparinase NUMBER chondroitin ABC lyase
AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. 	heparinase III	chondroitin ABC lyase	none	{'e1': {'word': 'heparinase III', 'word_index': [(6, 7)], 'id': 'DDI-MedLine.d190.s8.e1'}, 'e2': {'word': 'chondroitin ABC lyase', 'word_index': [(8, 10)], 'id': 'DDI-MedLine.d190.s8.e2'}, 'sentence_id': 'DDI-MedLine.d190.s8'}	AAV2 mediated retinal transduction improved co-injection heparinase NUMBER chondroitin ABC lyase
Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.	Implanon	antiretroviral	effect	{'e1': {'word': 'Implanon', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d208.s0.e0'}, 'e2': {'word': 'antiretroviral', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d208.s0.e1'}, 'sentence_id': 'DDI-MedLine.d208.s0'}	Implanon failure HIV positive woman antiretroviral therapy resulting NUMBER ectopic pregnancies
We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.	antiretroviral	Implanon	effect	{'e1': {'word': 'antiretroviral', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d208.s3.e0'}, 'e2': {'word': 'Implanon', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d208.s3.e1'}, 'sentence_id': 'DDI-MedLine.d208.s3'}	present interesting case HIV positive woman antiretroviral therapy tubal pregnancies NUMBER separate occasions Implanon place
"[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].
"	hemantane	doxycycline	none	{'e1': {'word': 'hemantane', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d214.s0.e0'}, 'e2': {'word': 'doxycycline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d214.s0.e1'}, 'sentence_id': 'DDI-MedLine.d214.s0'}	Influence hemantane doxycycline MPTP evoked behavior violations C57BL NUMBER mice
The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) 	anti-parkinsonian drug	hemantane	none	{'e1': {'word': 'anti-parkinsonian drug', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d214.s1.e0'}, 'e2': {'word': 'hemantane', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s1.e1'}, 'sentence_id': 'DDI-MedLine.d214.s1'}	effects anti-parkinsonian drug hemantane NUMBER adamantyl hexamethylenimine NUMBER mg / kg p. o.
The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) 	anti-parkinsonian drug	(2-adamantyl)hexamethylenimine	none	{'e1': {'word': 'anti-parkinsonian drug', 'word_index': [(1, 2)], 'id': 'DDI-MedLine.d214.s1.e0'}, 'e2': {'word': '(2-adamantyl)hexamethylenimine', 'word_index': [(4, 6)], 'id': 'DDI-MedLine.d214.s1.e2'}, 'sentence_id': 'DDI-MedLine.d214.s1'}	effects anti-parkinsonian drug hemantane NUMBER adamantyl hexamethylenimine NUMBER mg / kg p. o.
The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) 	hemantane	(2-adamantyl)hexamethylenimine	none	{'e1': {'word': 'hemantane', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s1.e1'}, 'e2': {'word': '(2-adamantyl)hexamethylenimine', 'word_index': [(4, 6)], 'id': 'DDI-MedLine.d214.s1.e2'}, 'sentence_id': 'DDI-MedLine.d214.s1'}	effects anti-parkinsonian drug hemantane NUMBER adamantyl hexamethylenimine NUMBER mg / kg p. o.
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	antibiotic drug	doxycycline	none	{'e1': {'word': 'antibiotic drug', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d214.s2.e0'}, 'e2': {'word': 'doxycycline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d214.s2.e1'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	antibiotic drug doxycycline NUMBER mg / kg p. o. well neurotoxin NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine MPTP NUMBER x NUMBER mg / kg i. p.
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	antibiotic drug	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	none	{'e1': {'word': 'antibiotic drug', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d214.s2.e0'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine', 'word_index': [(11, 19)], 'id': 'DDI-MedLine.d214.s2.e2'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	antibiotic drug doxycycline NUMBER mg / kg p. o. well neurotoxin NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine MPTP NUMBER x NUMBER mg / kg i. p.
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	antibiotic drug	MPTP	none	{'e1': {'word': 'antibiotic drug', 'word_index': [(0, 1)], 'id': 'DDI-MedLine.d214.s2.e0'}, 'e2': {'word': 'MPTP', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d214.s2.e3'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	antibiotic drug doxycycline NUMBER mg / kg p. o. well neurotoxin NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine MPTP NUMBER x NUMBER mg / kg i. p.
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	doxycycline	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	none	{'e1': {'word': 'doxycycline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d214.s2.e1'}, 'e2': {'word': '1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine', 'word_index': [(11, 19)], 'id': 'DDI-MedLine.d214.s2.e2'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	antibiotic drug doxycycline NUMBER mg / kg p. o. well neurotoxin NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine MPTP NUMBER x NUMBER mg / kg i. p.
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	doxycycline	MPTP	none	{'e1': {'word': 'doxycycline', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d214.s2.e1'}, 'e2': {'word': 'MPTP', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d214.s2.e3'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	antibiotic drug doxycycline NUMBER mg / kg p. o. well neurotoxin NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine MPTP NUMBER x NUMBER mg / kg i. p.
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	MPTP	none	{'e1': {'word': '1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine', 'word_index': [(11, 19)], 'id': 'DDI-MedLine.d214.s2.e2'}, 'e2': {'word': 'MPTP', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d214.s2.e3'}, 'sentence_id': 'DDI-MedLine.d214.s2'}	antibiotic drug doxycycline NUMBER mg / kg p. o. well neurotoxin NUMBER methyl NUMBER phenyl NUMBER NUMBER NUMBER NUMBER tetrahydropyridine MPTP NUMBER x NUMBER mg / kg i. p.
Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity. 	hemantane	doxycycline	effect	{'e1': {'word': 'hemantane', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d214.s5.e0'}, 'e2': {'word': 'doxycycline', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d214.s5.e1'}, 'sentence_id': 'DDI-MedLine.d214.s5'}	Acute administration hemantane doxycycline failed influence locomotion mice combination normalized motor activity
"Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
"	dacarbazine	imexon	none	{'e1': {'word': 'dacarbazine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d147.s0.e0'}, 'e2': {'word': 'imexon', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d147.s0.e1'}, 'sentence_id': 'DDI-MedLine.d147.s0'}	Interaction dacarbazine imexon vitro vivo human A375 melanoma cells
We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.	dacarbazine	DTIC	none	{'e1': {'word': 'dacarbazine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d147.s1.e0'}, 'e2': {'word': 'DTIC', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d147.s1.e1'}, 'sentence_id': 'DDI-MedLine.d147.s1'}	evaluated mechanisms interaction alkyating agent dacarbazine DTIC pro-oxidant imexon human A375 melanoma cell line
We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.	dacarbazine	imexon	none	{'e1': {'word': 'dacarbazine', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d147.s1.e0'}, 'e2': {'word': 'imexon', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d147.s1.e2'}, 'sentence_id': 'DDI-MedLine.d147.s1'}	evaluated mechanisms interaction alkyating agent dacarbazine DTIC pro-oxidant imexon human A375 melanoma cell line
We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.	DTIC	imexon	none	{'e1': {'word': 'DTIC', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d147.s1.e1'}, 'e2': {'word': 'imexon', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d147.s1.e2'}, 'sentence_id': 'DDI-MedLine.d147.s1'}	evaluated mechanisms interaction alkyating agent dacarbazine DTIC pro-oxidant imexon human A375 melanoma cell line
The effect of DTIC and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). 	DTIC	imexon	none	{'e1': {'word': 'DTIC', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d147.s2.e0'}, 'e2': {'word': 'imexon', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d147.s2.e1'}, 'sentence_id': 'DDI-MedLine.d147.s2'}	effect DTIC imexon alone combination evaluated growth inhibition MTT radiolabeled drug uptake cellular thiol content HPLC DNA strand breaks Comet assay
There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC. 	imexon	DTIC	none	{'e1': {'word': 'imexon', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d147.s6.e0'}, 'e2': {'word': 'DTIC', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d147.s6.e1'}, 'sentence_id': 'DDI-MedLine.d147.s6'}	> NUMBER % reduction cellular glutathione cysteine imexon DTIC
Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.	Imexon	dacarbazine	effect	{'e1': {'word': 'Imexon', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d147.s8.e0'}, 'e2': {'word': 'dacarbazine', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d147.s8.e1'}, 'sentence_id': 'DDI-MedLine.d147.s8'}	Imexon dacarbazine show additive effects vitro vivo human A375 melanoma cells
The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone. 	levothyroxine	simeticone	int	{'e1': {'word': 'levothyroxine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d181.s4.e0'}, 'e2': {'word': 'simeticone', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d181.s4.e1'}, 'sentence_id': 'DDI-MedLine.d181.s4'}	authors report case infant confirmed congenital hypothyroidism levothyroxine experienced possible drug interaction simeticone
Questioning revealed the child was taking Infacol drops before feeds while on levothyroxine. 	Infacol	levothyroxine	none	{'e1': {'word': 'Infacol', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d181.s6.e0'}, 'e2': {'word': 'levothyroxine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d181.s6.e1'}, 'sentence_id': 'DDI-MedLine.d181.s6'}	Questioning revealed child taking Infacol drops feeds levothyroxine
Drug interaction of thyroxine with simeticone has not been reported previously and is not listed in the British National Formulary for Children. 	thyroxine	simeticone	none	{'e1': {'word': 'thyroxine', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d181.s8.e0'}, 'e2': {'word': 'simeticone', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d181.s8.e1'}, 'sentence_id': 'DDI-MedLine.d181.s8'}	Drug interaction thyroxine simeticone reported previously listed British National Formulary Children
The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, cross-reacting material 197 (CRM197). 	cross-reacting material 197	CRM197	none	{'e1': {'word': 'cross-reacting material 197', 'word_index': [(16, 18)], 'id': 'DDI-MedLine.d201.s4.e0'}, 'e2': {'word': 'CRM197', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d201.s4.e1'}, 'sentence_id': 'DDI-MedLine.d201.s4'}	aim present study investigate whether HB EGF therapeutic target elucidate antitumor effects specific inhibitor HB EGF cross-reacting material NUMBER CRM197
We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of CRM197 on these cells alone or in combination with anticancer agent. 	CRM197	anticancer agent	none	{'e1': {'word': 'CRM197', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d201.s5.e0'}, 'e2': {'word': 'anticancer agent', 'word_index': [(12, 13)], 'id': 'DDI-MedLine.d201.s5.e1'}, 'sentence_id': 'DDI-MedLine.d201.s5'}	elucidated expression HB EGF cell lines evaluated effect CRM197 cells alone combination anticancer agent
CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. 	CRM197	CRM197	none	{'e1': {'word': 'CRM197', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d201.s9.e0'}, 'e2': {'word': 'CRM197', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d201.s9.e1'}, 'sentence_id': 'DDI-MedLine.d201.s9'}	CRM197 induced apoptosis furthermore combination CRM197 plus doxorubicin enhanced cytotoxicity cell line
CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. 	CRM197	doxorubicin	none	{'e1': {'word': 'CRM197', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d201.s9.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d201.s9.e2'}, 'sentence_id': 'DDI-MedLine.d201.s9'}	CRM197 induced apoptosis furthermore combination CRM197 plus doxorubicin enhanced cytotoxicity cell line
CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. 	CRM197	doxorubicin	effect	{'e1': {'word': 'CRM197', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d201.s9.e1'}, 'e2': {'word': 'doxorubicin', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d201.s9.e2'}, 'sentence_id': 'DDI-MedLine.d201.s9'}	CRM197 induced apoptosis furthermore combination CRM197 plus doxorubicin enhanced cytotoxicity cell line
"Amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.
"	Amphetamine	quinpirole	none	{'e1': {'word': 'Amphetamine', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d184.s0.e0'}, 'e2': {'word': 'quinpirole', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d184.s0.e1'}, 'sentence_id': 'DDI-MedLine.d184.s0'}	Amphetamine locomotor sensitization conditioned place preference adolescent male female rats neonatally treated quinpirole
The objective was to analyze the effects of neonatal quinpirole treatment on effects of amphetamine in adolescent rats using locomotor sensitization and conditioned place preference procedures. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d184.s2.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d184.s2.e1'}, 'sentence_id': 'DDI-MedLine.d184.s2'}	objective analyze effects neonatal quinpirole treatment effects amphetamine adolescent rats using locomotor sensitization conditioned place preference procedures
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	quinpirole	amphetamine	effect	{'e1': {'word': 'quinpirole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s5.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d184.s5.e1'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	female rats neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared quinpirole free controls sensitized amphetamine
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	quinpirole	quinpirole	none	{'e1': {'word': 'quinpirole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s5.e0'}, 'e2': {'word': 'quinpirole', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d184.s5.e2'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	female rats neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared quinpirole free controls sensitized amphetamine
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s5.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d184.s5.e3'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	female rats neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared quinpirole free controls sensitized amphetamine
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	amphetamine	quinpirole	none	{'e1': {'word': 'amphetamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d184.s5.e1'}, 'e2': {'word': 'quinpirole', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d184.s5.e2'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	female rats neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared quinpirole free controls sensitized amphetamine
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	amphetamine	amphetamine	none	{'e1': {'word': 'amphetamine', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d184.s5.e1'}, 'e2': {'word': 'amphetamine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d184.s5.e3'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	female rats neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared quinpirole free controls sensitized amphetamine
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(10, 10)], 'id': 'DDI-MedLine.d184.s5.e2'}, 'e2': {'word': 'amphetamine', 'word_index': [(14, 14)], 'id': 'DDI-MedLine.d184.s5.e3'}, 'sentence_id': 'DDI-MedLine.d184.s5'}	female rats neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared quinpirole free controls sensitized amphetamine
Male rats demonstrated sensitization to amphetamine, although this was muted compared with female rats, and were unaffected by neonatal quinpirole. 	amphetamine	quinpirole	none	{'e1': {'word': 'amphetamine', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d184.s6.e0'}, 'e2': {'word': 'quinpirole', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d184.s6.e1'}, 'sentence_id': 'DDI-MedLine.d184.s6'}	Male rats demonstrated sensitization amphetamine although muted compared female rats unaffected neonatal quinpirole
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s8.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d184.s8.e1'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated neonatal quinpirole enhanced time spent amphetamine paired context compared quinpirole free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	quinpirole	none	{'e1': {'word': 'quinpirole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s8.e0'}, 'e2': {'word': 'quinpirole', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d184.s8.e2'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated neonatal quinpirole enhanced time spent amphetamine paired context compared quinpirole free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s8.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d184.s8.e3'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated neonatal quinpirole enhanced time spent amphetamine paired context compared quinpirole free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d184.s8.e0'}, 'e2': {'word': 'amphetamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d184.s8.e4'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated neonatal quinpirole enhanced time spent amphetamine paired context compared quinpirole free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	amphetamine	quinpirole	none	{'e1': {'word': 'amphetamine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d184.s8.e1'}, 'e2': {'word': 'quinpirole', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d184.s8.e2'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated neonatal quinpirole enhanced time spent amphetamine paired context compared quinpirole free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	amphetamine	amphetamine	none	{'e1': {'word': 'amphetamine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d184.s8.e1'}, 'e2': {'word': 'amphetamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d184.s8.e3'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated neonatal quinpirole enhanced time spent amphetamine paired context compared quinpirole free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	amphetamine	amphetamine	none	{'e1': {'word': 'amphetamine', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d184.s8.e1'}, 'e2': {'word': 'amphetamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d184.s8.e4'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated neonatal quinpirole enhanced time spent amphetamine paired context compared quinpirole free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d184.s8.e2'}, 'e2': {'word': 'amphetamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d184.s8.e3'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated neonatal quinpirole enhanced time spent amphetamine paired context compared quinpirole free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	quinpirole	amphetamine	none	{'e1': {'word': 'quinpirole', 'word_index': [(11, 11)], 'id': 'DDI-MedLine.d184.s8.e2'}, 'e2': {'word': 'amphetamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d184.s8.e4'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated neonatal quinpirole enhanced time spent amphetamine paired context compared quinpirole free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 	amphetamine	amphetamine	none	{'e1': {'word': 'amphetamine', 'word_index': [(15, 15)], 'id': 'DDI-MedLine.d184.s8.e3'}, 'e2': {'word': 'amphetamine', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d184.s8.e4'}, 'sentence_id': 'DDI-MedLine.d184.s8'}	Rats treated neonatal quinpirole enhanced time spent amphetamine paired context compared quinpirole free controls conditioned amphetamine female controls conditioned amphetamine spent time drug paired context compared saline treated controls
"Interaction study of moxifloxacin and lomefloxacin with co-administered drugs.
"	moxifloxacin	lomefloxacin	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s0.e0'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(3, 3)], 'id': 'DDI-MedLine.d231.s0.e1'}, 'sentence_id': 'DDI-MedLine.d231.s0'}	Interaction study moxifloxacin lomefloxacin co-administered drugs
Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. 	Moxifloxacin	lomefloxacin	none	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s1.e0'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s1.e1'}, 'sentence_id': 'DDI-MedLine.d231.s1'}	Moxifloxacin lomefloxacin fluoroquinolone antibiotics used treating urinary respiratory tract infections
Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. 	Moxifloxacin	fluoroquinolone antibiotics	none	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s1.e0'}, 'e2': {'word': 'fluoroquinolone antibiotics', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d231.s1.e2'}, 'sentence_id': 'DDI-MedLine.d231.s1'}	Moxifloxacin lomefloxacin fluoroquinolone antibiotics used treating urinary respiratory tract infections
Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. 	lomefloxacin	fluoroquinolone antibiotics	none	{'e1': {'word': 'lomefloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s1.e1'}, 'e2': {'word': 'fluoroquinolone antibiotics', 'word_index': [(2, 3)], 'id': 'DDI-MedLine.d231.s1.e2'}, 'sentence_id': 'DDI-MedLine.d231.s1'}	Moxifloxacin lomefloxacin fluoroquinolone antibiotics used treating urinary respiratory tract infections
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	fluoroquinolones	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'fluoroquinolones', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	sucralfate	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'sucralfate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	gelusil	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'gelusil', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	erythromycin	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	moxifloxacin	multi minerals	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s3.e0'}, 'e2': {'word': 'multi minerals', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	fluoroquinolones	sucralfate	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'e2': {'word': 'sucralfate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	fluoroquinolones	gelusil	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'e2': {'word': 'gelusil', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	fluoroquinolones	erythromycin	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'e2': {'word': 'erythromycin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	fluoroquinolones	multi minerals	none	{'e1': {'word': 'fluoroquinolones', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s3.e1'}, 'e2': {'word': 'multi minerals', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	sucralfate	gelusil	none	{'e1': {'word': 'sucralfate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'e2': {'word': 'gelusil', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	sucralfate	erythromycin	none	{'e1': {'word': 'sucralfate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'e2': {'word': 'erythromycin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	sucralfate	multi minerals	none	{'e1': {'word': 'sucralfate', 'word_index': [(6, 6)], 'id': 'DDI-MedLine.d231.s3.e2'}, 'e2': {'word': 'multi minerals', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	gelusil	erythromycin	none	{'e1': {'word': 'gelusil', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'e2': {'word': 'erythromycin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	gelusil	multi minerals	none	{'e1': {'word': 'gelusil', 'word_index': [(7, 7)], 'id': 'DDI-MedLine.d231.s3.e3'}, 'e2': {'word': 'multi minerals', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 	erythromycin	multi minerals	none	{'e1': {'word': 'erythromycin', 'word_index': [(8, 8)], 'id': 'DDI-MedLine.d231.s3.e4'}, 'e2': {'word': 'multi minerals', 'word_index': [(9, 10)], 'id': 'DDI-MedLine.d231.s3.e5'}, 'sentence_id': 'DDI-MedLine.d231.s3'}	moxifloxacin lomefloxacin fluoroquinolones interaction study carried sucralfate gelusil erythromycin multi minerals
The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. 	moxifloxacin	lomefloxacin	none	{'e1': {'word': 'moxifloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s6.e0'}, 'e2': {'word': 'lomefloxacin', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d231.s6.e1'}, 'sentence_id': 'DDI-MedLine.d231.s6'}	response moxifloxacin lomefloxacin interaction co-administered drugs different conditions temperature noted using Shimadzu HPLC system PDA detector
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	Lomefloxacin	none	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'Lomefloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	sucralfate	mechanism	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'sucralfate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	gelusil	mechanism	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'gelusil', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	erythromycin	mechanism	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Moxifloxacin	multi-minerals	mechanism	{'e1': {'word': 'Moxifloxacin', 'word_index': [(0, 0)], 'id': 'DDI-MedLine.d231.s8.e0'}, 'e2': {'word': 'multi-minerals', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Lomefloxacin	sucralfate	mechanism	{'e1': {'word': 'Lomefloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'e2': {'word': 'sucralfate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Lomefloxacin	gelusil	mechanism	{'e1': {'word': 'Lomefloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'e2': {'word': 'gelusil', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Lomefloxacin	erythromycin	mechanism	{'e1': {'word': 'Lomefloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'e2': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	Lomefloxacin	multi-minerals	mechanism	{'e1': {'word': 'Lomefloxacin', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d231.s8.e1'}, 'e2': {'word': 'multi-minerals', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	sucralfate	gelusil	none	{'e1': {'word': 'sucralfate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'e2': {'word': 'gelusil', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	sucralfate	erythromycin	none	{'e1': {'word': 'sucralfate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'e2': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	sucralfate	multi-minerals	none	{'e1': {'word': 'sucralfate', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d231.s8.e2'}, 'e2': {'word': 'multi-minerals', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	gelusil	erythromycin	none	{'e1': {'word': 'gelusil', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'e2': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	gelusil	multi-minerals	none	{'e1': {'word': 'gelusil', 'word_index': [(5, 5)], 'id': 'DDI-MedLine.d231.s8.e3'}, 'e2': {'word': 'multi-minerals', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 	erythromycin	multi-minerals	none	{'e1': {'word': 'erythromycin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d231.s8.e4'}, 'e2': {'word': 'multi-minerals', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d231.s8.e5'}, 'sentence_id': 'DDI-MedLine.d231.s8'}	Moxifloxacin Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals neutral media
"Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
"	celecoxib	anti-cancer drugs	effect	{'e1': {'word': 'celecoxib', 'word_index': [(1, 1)], 'id': 'DDI-MedLine.d217.s0.e0'}, 'e2': {'word': 'anti-cancer drugs', 'word_index': [(3, 4)], 'id': 'DDI-MedLine.d217.s0.e1'}, 'sentence_id': 'DDI-MedLine.d217.s0'}	Interaction celecoxib different anti-cancer drugs antagonistic breast cancer cells
This study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents. 	cyclooxygenase-2 inhibitors	chemotherapeutic agents	none	{'e1': {'word': 'cyclooxygenase-2 inhibitors', 'word_index': [(3, 5)], 'id': 'DDI-MedLine.d217.s2.e0'}, 'e2': {'word': 'chemotherapeutic agents', 'word_index': [(11, 12)], 'id': 'DDI-MedLine.d217.s2.e1'}, 'sentence_id': 'DDI-MedLine.d217.s2'}	study investigates ability cyclooxygenase NUMBER inhibitors sensitize cells different origins several chemotherapeutic agents
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-FU	cisplatin	none	{'e1': {'word': '5-FU', 'word_index': [(16, 17)], 'id': 'DDI-MedLine.d217.s4.e0'}, 'e2': {'word': 'cisplatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d217.s4.e1'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	sensitivity cell cycle apoptosis DNA damage NUMBER different cancer cell lines HeLa HCT116 HepG2 MCF7 U251 NUMBER FU cisplatin doxorubicin etoposide celecoxib following different incubation schedules analyzed
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-FU	doxorubicin	none	{'e1': {'word': '5-FU', 'word_index': [(16, 17)], 'id': 'DDI-MedLine.d217.s4.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d217.s4.e2'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	sensitivity cell cycle apoptosis DNA damage NUMBER different cancer cell lines HeLa HCT116 HepG2 MCF7 U251 NUMBER FU cisplatin doxorubicin etoposide celecoxib following different incubation schedules analyzed
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-FU	etoposide	none	{'e1': {'word': '5-FU', 'word_index': [(16, 17)], 'id': 'DDI-MedLine.d217.s4.e0'}, 'e2': {'word': 'etoposide', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d217.s4.e3'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	sensitivity cell cycle apoptosis DNA damage NUMBER different cancer cell lines HeLa HCT116 HepG2 MCF7 U251 NUMBER FU cisplatin doxorubicin etoposide celecoxib following different incubation schedules analyzed
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	5-FU	celecoxib	none	{'e1': {'word': '5-FU', 'word_index': [(16, 17)], 'id': 'DDI-MedLine.d217.s4.e0'}, 'e2': {'word': 'celecoxib', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d217.s4.e4'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	sensitivity cell cycle apoptosis DNA damage NUMBER different cancer cell lines HeLa HCT116 HepG2 MCF7 U251 NUMBER FU cisplatin doxorubicin etoposide celecoxib following different incubation schedules analyzed
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	cisplatin	doxorubicin	none	{'e1': {'word': 'cisplatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d217.s4.e1'}, 'e2': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d217.s4.e2'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	sensitivity cell cycle apoptosis DNA damage NUMBER different cancer cell lines HeLa HCT116 HepG2 MCF7 U251 NUMBER FU cisplatin doxorubicin etoposide celecoxib following different incubation schedules analyzed
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	cisplatin	etoposide	none	{'e1': {'word': 'cisplatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d217.s4.e1'}, 'e2': {'word': 'etoposide', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d217.s4.e3'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	sensitivity cell cycle apoptosis DNA damage NUMBER different cancer cell lines HeLa HCT116 HepG2 MCF7 U251 NUMBER FU cisplatin doxorubicin etoposide celecoxib following different incubation schedules analyzed
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	cisplatin	celecoxib	none	{'e1': {'word': 'cisplatin', 'word_index': [(18, 18)], 'id': 'DDI-MedLine.d217.s4.e1'}, 'e2': {'word': 'celecoxib', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d217.s4.e4'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	sensitivity cell cycle apoptosis DNA damage NUMBER different cancer cell lines HeLa HCT116 HepG2 MCF7 U251 NUMBER FU cisplatin doxorubicin etoposide celecoxib following different incubation schedules analyzed
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	doxorubicin	etoposide	none	{'e1': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d217.s4.e2'}, 'e2': {'word': 'etoposide', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d217.s4.e3'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	sensitivity cell cycle apoptosis DNA damage NUMBER different cancer cell lines HeLa HCT116 HepG2 MCF7 U251 NUMBER FU cisplatin doxorubicin etoposide celecoxib following different incubation schedules analyzed
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	doxorubicin	celecoxib	none	{'e1': {'word': 'doxorubicin', 'word_index': [(19, 19)], 'id': 'DDI-MedLine.d217.s4.e2'}, 'e2': {'word': 'celecoxib', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d217.s4.e4'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	sensitivity cell cycle apoptosis DNA damage NUMBER different cancer cell lines HeLa HCT116 HepG2 MCF7 U251 NUMBER FU cisplatin doxorubicin etoposide celecoxib following different incubation schedules analyzed
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.	etoposide	celecoxib	none	{'e1': {'word': 'etoposide', 'word_index': [(20, 20)], 'id': 'DDI-MedLine.d217.s4.e3'}, 'e2': {'word': 'celecoxib', 'word_index': [(21, 21)], 'id': 'DDI-MedLine.d217.s4.e4'}, 'sentence_id': 'DDI-MedLine.d217.s4'}	sensitivity cell cycle apoptosis DNA damage NUMBER different cancer cell lines HeLa HCT116 HepG2 MCF7 U251 NUMBER FU cisplatin doxorubicin etoposide celecoxib following different incubation schedules analyzed
We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. 	celecoxib	celecoxib	none	{'e1': {'word': 'celecoxib', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d217.s5.e0'}, 'e2': {'word': 'celecoxib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d217.s5.e1'}, 'sentence_id': 'DDI-MedLine.d217.s5'}	found antagonism celecoxib NUMBER drugs breast cancer cells MCF7 following incubation schedules celecoxib doxorubicin cell lines except NUMBER combinations HCT116 cells
We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. 	celecoxib	doxorubicin	none	{'e1': {'word': 'celecoxib', 'word_index': [(2, 2)], 'id': 'DDI-MedLine.d217.s5.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d217.s5.e2'}, 'sentence_id': 'DDI-MedLine.d217.s5'}	found antagonism celecoxib NUMBER drugs breast cancer cells MCF7 following incubation schedules celecoxib doxorubicin cell lines except NUMBER combinations HCT116 cells
We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. 	celecoxib	doxorubicin	effect	{'e1': {'word': 'celecoxib', 'word_index': [(12, 12)], 'id': 'DDI-MedLine.d217.s5.e1'}, 'e2': {'word': 'doxorubicin', 'word_index': [(13, 13)], 'id': 'DDI-MedLine.d217.s5.e2'}, 'sentence_id': 'DDI-MedLine.d217.s5'}	found antagonism celecoxib NUMBER drugs breast cancer cells MCF7 following incubation schedules celecoxib doxorubicin cell lines except NUMBER combinations HCT116 cells
These results, if confirmed in-vivo, indicate that celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers. 	celecoxib	doxorubicin	none	{'e1': {'word': 'celecoxib', 'word_index': [(4, 4)], 'id': 'DDI-MedLine.d217.s11.e0'}, 'e2': {'word': 'doxorubicin', 'word_index': [(9, 9)], 'id': 'DDI-MedLine.d217.s11.e1'}, 'sentence_id': 'DDI-MedLine.d217.s11'}	results confirmed vivo indicate celecoxib suitable chemosensitizer breast cancer doxorubicin cancers
